Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory
Ramesh C. Gupta
Rajiv Lall
Ajay Srivastava2 - 1Toxicology Department, Breathitt Veterinary Center, Murray State University, Hopkinsville, KY, United States
- 2Vets Plus, Inc., Menomonie, WI, United States
Hyaluronic acid (also known as hyaluronan or hyaluronate) is naturally found in many tissues and fluids, but more abundantly in articular cartilage and synovial fluid (SF). Hyaluronic acid (HA) content varies widely in different joints and species. HA is a non-sulfated, naturally occurring non-protein glycosaminoglycan (GAG), with distinct physico-chemical properties, produced by synoviocytes, fibroblasts, and chondrocytes. HA has an important role in the biomechanics of normal SF, where it is partially responsible for lubrication and viscoelasticity of the SF. The concentration of HA and its molecular weight (MW) decline as osteoarthritis (OA) progresses with aging. For that reason, HA has been used for more than four decades in the treatment of OA in dogs, horses and humans. HA produces anti-arthritic effects via multiple mechanisms involving receptors, enzymes and other metabolic pathways. HA is also used in the treatment of ophthalmic, dermal, burns, wound repair, and other health conditions. The MW of HA appears to play a critical role in the formulation of the products used in the treatment of diseases. This review provides a mechanism-based rationale for the use of HA in some disease conditions with special reference to OA.
Introduction
In 1934, Karl Meyer and John Palmer isolated for the first time a glycosaminoglycan (GAG) from the vitreous humor of the bovine eye and named it “hyaluronic acid” (derived from hyaloid [vitreous] and uronic acid). The term “hyaluronan” was introduced in 1986 to conform to polysaccharide nomenclature. Subsequently, it was found in other organs (joints, skin, rooster comb, human umbilical cord, etc.) and tissues (connective, epithelial, and nervous). Hyaluronic acid (HA) is also produced via microbial (Streptococcus zooepidemicus, Escherichia coli, Bacillus subtilis, and others) fermentation (1–3), and its molecular weight (MW) is reported to be controlled by UDP-N-acetylglucosamine concentration (4). In both vertebrates and bacteria, its chemical structure is identical (5, 6). Most cells in the body have the capability to synthesize HA during some point of their cell cycles, implicating its function in several fundamental biological processes (7–10). HA is a major component of the extracellular matrix (ECM) and is normally present in mammalian bone marrow, articular cartilage, and synovial fluid.
The first therapeutic injections of HA in animal joints were performed on track horses for traumatic arthritis. This treatment proved effective and since then it has been widely used in veterinary medicine (11, 12). Currently, elastoviscous HA solutions and its derivatives (such as Hylans) are commonly used in animals for treatment of arthritic pain. HA is reported to be a unique biomolecule because its biological functions can be attributed to its physico-chemical properties and to its specific interactions with cells and ECM (7, 10, 13). HA has recently become more widely accepted in the armamentarium of therapies for OA pain (14, 15). In humans, HA has been used since the 1970s for treating joint pain and other health conditions (8, 10, 16–22).
This review describes physico-chemical and rheological properties, cellular and molecular mechanisms in pharmacological and therapeutic effects in health and disease conditions, and toxicity and safety considerations of HA.
Physico-Chemical Properties and Physiological Functions
Hyaluronic acid (HA) is a naturally occurring non-sulfated glycosaminoglycan (GAG) non-protein compound with distinct physico-chemical properties of repeating β-1,4-D-glucuronic acid and β-1,3-N-acetylglucosamine units (10, 16, 23–25). The structural formula of HA is shown in Figure 1. HA has excellent viscoelasticity, high moisture retention capacity, high biocompatibility, and hygroscopic properties (16, 26). At a concentration as low as 0.1%, HA chains can provide high viscosity (23). By having these properties, HA acts as a lubricant, shock absorber, joint structure stabilizer, and water balance- and flow resistance-regulator (3, 27, 28).
Figure 1. Structural formula of hyaluronic acid (HA).
A person with an average weight of 70 kg has about 15 g of HA, which is present in joints, skin, eyes and other organs and tissues (connective, epithelial, and neural) of the body (7, 29, 30). Out of 15 g total HA, 5 g turns over daily (31). The greatest amount of HA is present in the skin (about half of the total HA (32), synovial fluid (33), the vitreous body (34), and the umbilical cord (35). HA is an important constituent of ECM and contributes to cell proliferation, migration, and morphogenesis (10, 36–38). HA also occurs within cells and it has been reported to have roles inside the cell (37, 39). Within the joint cavity, HA molecules are predominately synthesized by type B synoviocytes. HA (a polymer of disaccharides) can be 25,000 disaccharide repeats in length with a MW of 5,000–20,000,000 Da.
HA is synthesized by hyaluronan synthase (HAS), of which vertebrates have three isozymes (HAS-1, HAS-2, and HAS-3). These three HAS isozymes produce different size HA polymers and are differentially regulated by transcriptional, translational and post-translational levels, including alternative splicing, sub-cellular localization and epigenetic processes. These isoenzymes lengthen HA by repeatedly adding glucuronic acid and N-acetylglucosamine to the nascent polysaccharide. The three genes are located on three different chromosomes, even though they have 50–71% identity. They occur at 19q13.4, 8q24.12, and 16q22.1, respectively (40). HA is catabolized by hyaluronidases, and the MW of HA in cartilage is reported to decrease with age (8, 41–44).
HA binds to ECM molecules and cell surface receptors, thereby regulating cellular behavior via control of the tissue's macro- and micro-environments (7). In an in vitro study, Sommarin and Heinegård (45) investigated the interaction between HA and exogenous [35S]sulfate-labeled cartilage proteoglycans (PGs) at the calf articular-cartilage chondrocyte cell surface. Findings revealed that PGs interact with HA receptors at the cell surface in the HA-binding region. The bound 35S-labeled PGs are located at the cell surface, and only small proportions of the PGs are internalized. HA can bind to three main classes of cell surface receptors: (1) CD44 (a membrane glycoprotein), (2) receptor for hyaluronate-mediated motility (RHAMM), and (3) Intercellular Adhesion Molecule 1 (ICAM-1), which perform different functions (7, 46). CD44 is the most widely distributed cell surface receptor recognized for HA binding (8, 10, 47–49). CD44 interacts with a number of other ligands including osteopontin, collagens and matrix metalloproteinases (MMPs). HA may inhibit signal transduction through CD44 (50, 51) and RHAMM (52, 53) HA receptors. It is reported that higher- and lower- MW HA have distinct molecular and cellular mechanisms and diverse biological effects through interaction with CD44 receptors (54–56). CD44-mediated signaling affects both chondrocyte survival pathways as well as apoptotic (chondroptotic) pathways. Fragments of HA produced in free radical processes have the potential to augment the production of nitric oxide (NO) in a CD44-dependent mechanism. In regard to defining functional chondrocyte CD44, future studies need to include analysis of the variant CD44 isoforms expression, phosphorylation, cytoskeletal interactions, occupancy, and turnover. In addition to these receptors, two other receptors have been identified for HA binding: (1) lymphatic vessel endothelial hyaluronan receptor (LYVE-1), and (2) hyaluronic acid receptor for endocytosis (HARE), also known as Stabilin-2 (40).
Physiological roles of HA are well-characterized in body tissues and fluids (7, 27, 57). In general, HA may be involved in various cellular interactions (cell differentiation, proliferation, development, and recognition) and physiological functions (lubrication, hydration balance, matrix structure, and steric interactions) (58). By having unique rheological properties and being a constituent of GAG and articular cartilage, the physiological roles of HA are well-explained in normal structure and function of joints. The physiological relevance of HA is not only recognized in healthy and OA joints (14, 57–60), but also in other tissues and health conditions (7, 8, 10, 36, 61, 62).
Physiological and pharmacological mechanisms involved in effects of HA in SF are summarized in Table 1.
Table 1. Physiological and pharmacological mechanisms and effects of HA in synovial fluid.
All these physico-chemical properties of HA have been shown to be MW-dependent (10, 25, 79, 80). Aviad and Houpt (81) suggested that the beneficial effect of injected HA in joint disease, such as OA, may be due to pharmacological effects rather than to physico-chemical properties (such as SF viscosity, HA concentration, HA MW, and the rate of synthesis). Taken together, findings suggest that the beneficial effects of HA may be due to both rheological properties and pharmacological mechanisms.
Pharmacokinetics of HA
Pharmacokinetic data of HA in animals and humans are sparse. Balogh et al. (82) reported for the first time pharmacokinetics (absorption, distribution and excretion) of higher-MW 99mtechnetium HA (99mTc-HA) in Wistar rats (150–200 g each) and Beagle dogs (10–15 kg each) after oral administration. The MW of this preparation was in the range of HA similar to that used in some dietary supplements. All tissues examined showed incorporation of radioactivity from 99mTc-HA starting at 15 min and persisting for 48 h. The whole body scintigraphs and close-ups of the ventral chest region showed non-alimentary radioactivity from 99mTc-HA concentrated in joints, vertebrae and salivary glands 4 h after administration. HA, which is known to have an affinity for connective tissues, exhibited accumulation of radioactivity after oral administration. Balogh et al. (82) also noted that the appearance of radioactivity in tissues before blood suggested that HA was delivered to tissues via a non-blood transport system. Lymphatic uptake and transport could explain these findings. It is also known that transport of higher-MW HA into and out of synovial spaces occurs via lymphatics (83–85) and its normal presence in blood and other fluids (83) provides mechanistic support for the appearance of ingested HA in connective tissues (82). In a number of studies, the distribution of intravenously (IV) administered HA has been studied using 14C, 3H, 125I, and other isotopes as tracers (86–88). In a rat model (adult male Wistar rats weighing 280–350 g each), Svanovsky et al. (89) determined the difference in the biodistributional pathways of 111In-labeled diethylenetriamine pentaacetic acid-HA (111In-DTPA-HA) molecule of three different MWs (10, 100, and 450 kDa). The study revealed that 50–54% for 10 and 100 kDa, and 80% for 450 kDa of the administered dose of radiolabel HA was present in the liver after 5 min. The elimination of radiolabel was mostly renal and in lower-MW form. Radioactivity remained in liver throughout the 72 h experimental period. Authors concluded that a difference in the biodistribution of 450 kDa and lower-MW radiolabelled molecules was found. Higher amounts of radiolabel were taken up by the liver when the 450 kDa molecule was used, and lower-MW fractions were found in the urine, which could have been products of non-enzymatic cleavage. In an in vitro study, Eriksson et al. (90) confirmed that uptake of radiolabelled HA occurred in the liver endothelial cells, and the same cells degraded the HA into lower-MW HA products.
In an experimental study, Engström-Laurent and Hellström (91) determined the concentration of circulating HA in male Sprague-Dawley rats (weighing 300–350 g each) after either the liver or the kidneys had been excluded from the systemic circulation. The rate of increase was more rapid in the animals with ligated hepatic vessels compared to those with ligated renal vessels. This and other studies suggested that both renal and hepatic systems are important for the removal of HA from the blood (83).
In a dialysis study in rats, Breborowicz et al. (92) found that 25% of the administered HA (10 mg/dL; MW 1,800,000–2,400,000) was absorbed over a period of 8 h, suggesting significant absorption of HA from peritoneal interstitium to bloodstream.
Pierce (93) revealed elevated levels of HA in serum after its oral administration in horses. Therapeutic efficacy of HA against lameness was found to be greater with oral than IV administration. Furthermore, HA administered intra-articularly (IA) dissipates out of the joint within 14–18 h. HA diffuses out into surrounding tissues via the bloodstream, circulating throughout the body, and is rapidly eliminated.
In normal adult humans and rabbits, Fraser et al. (94) determined the plasma elimination half-life of HA in between 2.5 and 5.5 min after injection of [3H]HA with higher-MW. Reed et al. (95) also reported the half-life of circulating HA in between 3 and 5 min in rabbits injected with [3H]HA subcutaneously. The daily turnover of HA in the circulation was estimated to be at least 150 mg. Elimination of HA was predominantly extra-renal, with the upper MW limit for renal excretion being 25,000 Da. Findings revealed that the liver removes ~90% of the circulating HA and the remainder is removed by the spleen within 24 h. HA can be catabolized by three hyaluronidases (HYAL) (96): (1) HYAL1 is associated with lysosomes, which degrades the HA into tetrasaccharides, (2) HYAL2 degrades HA of higher-MW into products of 20 kDa (97), and (3) details of HAYL3 have yet to be elucidated (98). HA in the amounts currently used for therapeutic purposes does not appear to accumulate significantly in the circulation.
Pharmacotherapeutics of HA
Hyaluronic Acid (HA) in Osteoarthritis (OA)
OA Background
OA is an inflammatory disease of diarthrodial joints characterized by chronic and progressive cartilage degeneration, osteophyte formation, subchondral sclerosis, hypertrophy of bone at the margin, and changes in the synovial membrane (42, 99). With age-related OA, the articular cartilage is subject to significant structural, mechanical, and matrix changes consisting of mild fibrillation of the articular surface and a decrease in PG monomer size and aggregation (100). OA is a disease of the entire joint affecting the articular cartilage, subchondral bone, synovial capsule and membrane, and the periarticular tissues (connective and muscular), and soft tissues (such as ligaments, tendons, and in the menisci) (42–44, 101–103). Risk factors include aging, breed, obesity, joint injury, nutrition and genetics.
Currently, one out of five dogs or horses suffer from OA. Also, 52.5 million people in the US (10–12% of the adult population; 40% of individuals aged 50 years and over) and 250 million people worldwide have symptomatic OA (104–107).
Before discussing the anti-arthritic effects of HA, it is necessary to describe briefly the pathophysiology of OA. Pathophysiology of OA is very complex and it has been studied for decades, yet precise pathways and mechanisms have yet to be fully understood (42–44, 103, 108, 109). Horton et al. (100) described cellular, molecular, and matrix changes in OA. Aging and inflammation (inflammaging) and oxidative stress appear to be major contributing factors to the development and progression of OA (99, 110). Increases in proteolytic/catabolic enzymes (such as collagenases, aggrecanases, and matrix metalloproteinases), oxidative (superoxide and hydrogen peroxide) and nitrosative (nitric oxide and peroxynitrite) stress, inflammatory cytokines (IL-1β, TNF-α, and leptin), PGE2, cAMP, TSG-6, NF-κB, toll-like receptors (TLR), EP4 receptor, adiponectin, and many other molecular pathways (MAPK, NF-κB, TGFβ, Wnt/β-catenin, JNK, p38, NUDT7-PGAM1 axis, HIF-1α:CRAT:miR-144-3p axis dysregulation, and others) are involved in the pathogenesis of OA (42–44, 65, 109, 111–119). In several studies, some miRNAs have been implicated in development of OA (120–124), while others are involved in suppression of OA (125, 126).
Apoptosis (programmed cell death) of chondrocytes (chondroptosis) has also been reported to be a major factor in the degeneration and failure of articular cartilage in OA (127–132). The common molecular inducers of chondroptosis may include ROS, RNS, cytokines [IL-1β, TNF-α, TNF-related apoptosis-inducing ligand (TRAIL), and Fas ligand], and mechanical stress (131). In an in vitro study, Miwa et al. (133) demonstrated that chondroptosis appears to be due to elevated PGE2 through a cAMP-dependent pathway. In addition to this inflammatory pathway, mitochondrial dysfunction pathway leading to oxidative stress is another contributing factor to chondroptosis (134). Hashimoto et al. (135) and Kim et al. (129) reported that the collagen framework is important in the maintenance of chondrocyte survival in cartilage, and upregulation of Fas ligand in matrix depleted specimens suggested that the Fas pathway may have a role in chondroptosis induced by matrix depletion. In another study, Blanco et al. (127) found that IL-1-stimulated chondroptosis occurs due to excess generation of NO. Excess NO and ROS are reported to suppress mitochondrial activity (136, 137) and cartilage matrix synthesis, and enhance MMPs activity (131, 138). Of course, mitochondrial activity can also be modulated by IL-1β and TNF-α in chondrocytes (139). In late-stage OA, the cartilage becomes hypocellular, often accompanied by lacunar emptying, which has been considered as evidence that chondrocyte death is a central feature in OA progression. Chondroptosis is also characterized by increases in caspase-3 and−8, DNA fragmentation, increases in MMPs and ADAMTS, and decreases in aggrecan and type II collagen. It remains unclear whether chondroptosis is a cause or consequence of cartilage degeneration in OA (131, 140).
OA is characterized by the degradation of cartilage matrix components (including cartilage-specific type II collagen and the PG aggrecan), resulting in the loss of cartilage structure and function (42, 43, 141). ECM loss occurs due to elevated enzyme (collagenases, aggrecanases, and MMPs) activity. Chondrocyte death and ECM loss may form a vicious cycle, with the progression of one aggravating the other, and there appears to be a correlation between the degree of cartilage damage and chondroptosis (131).
Reversal of some of these mechanisms (as described above) provides the rationale for the use HA in OA.
HA Viscosupplementation, Mechanism of Action, and Pharmacological Effects
Rheological properties of HA and OA therapy
Rheological properties (such as MW, concentration, and viscoelasticity) of HA/HA derivatives (hereafter called HA) in formulation and route of administration are major determining factors for successful therapy of OA (10, 57, 142–145). The degree of anti-inflammatory, immunomodulatory, analgesic, and anti-OA effects of HA are also reported to be determined by the MW of HA and route of administration (25, 55, 78, 82, 107, 146–149).
Because OA affects a limited number of joints (such as shoulder, elbow, stifle, hip, hands and feet), local treatment, such as an IA HA delivery system, has been reported to be of paramount importance (150–152). IA administration is reported to be more effective than oral or IV because it avoids systemic exposure and potential adverse side effects. IA treatment with HA has been investigated in a number of studies, and it has been used for decades as OA therapy in dogs, horses, and humans (153–156). The concept of viscosupplementation, first proposed by Balazs and Denlinger (73), is based upon the hypothesis that IA injection of HA into OA joints could restore the rheological properties of the SF, promote the endogenous synthesis of a higher MW and possibly more functional HA, thereby improving mobility, and articular function, and decreasing pain.
Some studies revealed that HA with a MW larger than that of the injected solution were found in the SF of humans (72) and animals (71, 74). Although, HA concentrations remained within the physiological range. Since the concentration and MW of HA are significantly reduced in SF of OA (128, 164, 166, 184), viscosupplementation by IA injections of HA was recognized as a useful therapeutic option in the treatment of OA in different joints of several species (58, 66, 74, 157–159). In SF, HA is the major chemical component produced by synoviocytes, fibroblasts, and chondrocytes. Native HA has a MW of 4,000,000–10,000,000 Da, and is present in articular fluid in a concentration of about 0.35 g/100 mL (160). Within the normal adult knee, there is ~2 mL of SF, with a HA concentration of 2.5–4.0 mg/mL (158). In equines, the HA concentration in joints can be in the range of 0.33–1.5 mg/mL (161) and MW in the range of 2,000,000–3,000,000 Da.
In horses, the concentration of HA is reported to be significantly lower in arthritic joints (162). In OA, synovial HA is depolymerized (MW, 2,700–4,500 kDa) and cleared at higher rates (11–12 h) than normal (20 h) (27, 73, 158). An amphiphilic HA derivative was prepared by the amidation of the carboxylic group of the glucuronic acid called HYADD4-G (HY4). Borzacchiello et al. (74) compared viscoelastic properties of HY4 at a concentration of 5 mg/mL in phosphate buffered saline with solutions of native HA having the same MW. The addition of HY4 to equine SF increased its viscoelasticity at all the SF:HY4 ratios tested, thereby increasing the SF rheology presenting a new option in viscosupplementation therapy of OA. In sheep, IA HA is reported to be cleared from the acutely inflammed synovial joint within 20 h (157). These changes are known to reduce the viscoelasticity of the SF in OA (106, 163). It needs to be mentioned that SF HA concentration should not be used as a diagnostic biomarker of OA (164) since HA concentration can be influenced by other disease conditions.
Previous studies suggested that a more potent symptomatic effect was noted with higher-MW HA preparations, as compared to those of lower- or intermediate-MW HA (155, 165–167). Ghosh and Guidolin (25) demonstrated that HA with MWs in the range of 500,000–1,000,000 Da partially restored SF rheological properties and synovial fibroblast metabolism in animal models.
Tikiz et al. (168) compared the efficacy of IA injections of a lower-MW HA (Ostenil) with a higher-MW viscosupplement (Hylan-G-F 20, Synvisc) in hip OA. Findings revealed that both types of viscosupplementation produced a significant clinical improvement during the 6-months follow-up period, however, one formulation was not better than the other. In a similar study, Gigis et al. (77) reported that IA injections using higher-MW or lower-MW can improve joint function and reduce stiffness and pain in patients suffering from knee OA, however, no clear difference in benefits seems to exist between the two preparations and neither can slow disease progression based on radiological findings. Maheu et al. (159) compared the efficacy and safety of two different MW HA (F60027 and Hylan G-F20) in knee OA patients. Findings revealed that both preparations were equally effective in reducing functional impairment and relieving pain.
Bagga et al. (59) reported that the lower-MW HA preparations (500,000–1,500,000 Da) can achieve maximum concentration in the joint and are thought to reduce inflammation, however, they present lower elastoviscosity than native HA. Higher-MW preparations (6,000,000–7,000,000 Da) result in a better increase in fluid retention in the joint and possibly a stronger anti-inflammatory effect (66). In essence, efficacy might be related to rheological properties including MW and viscoelasticity of the preparation (169, 170). There is controversy over the efficacy of orally administered HA. Pharmacokinetic data revealed that orally administered higher-MW HA also reached the joint (82), which provides a rationale for the oral supplementation of HA.
From these studies, it can be concluded that viscosupplementation properties of HA therapy is more effective via IA than oral or IV administration, which can be due to augmentation of the lubricating potential of the SF in the OA joint (76). More studies need to be done to elucidate the role of MW of HA in viscosupplementation.
Mechanisms-based anti-OA effects of HA are summarized in Table 2.
Table 2. Mechanisms-based anti-OA effects of HA (some important studies).
Antioxidative, Anti-inflammatory, and Analgesic Effects of HA
It is well-established that oxidative/nitrosative stress and inflammation are involved in OA-cartilage degeneration. In surgically-induced OA in New Zealand white rabbits, Takahashi et al. (65) found that the amount of nitric oxide (NO) produced by the meniscus was much greater than that produced by the synovium. Also, NO production in the meniscus and synovium of the HA group were significantly lower than those without HA treatment. The results suggested that the inhibition of NO production in meniscus and synovium might be a part of the mechanism of the therapeutic effect of HA on OA. In addition to NO (65, 111, 175), superoxide and hydroxyl radicals are also reported to be involved in the pathogenesis of OA, and their levels are reduced by HA treatment (111, 134, 171, 176, 177).
Philip (165), Ghosh and Guidolin (25), and Jerosch (155) reported that HA exerts pharmacologic actions by mitigating the activities of pro-inflammatory mediators and pain producing neuropeptides released by activated synovial cells (42–44, 154). These authors also described the interaction of HA with HA/pain receptors and analgesic effects. Moreland (14) noted that HA can reduce nerve impulses and nerve sensitivity associated with the pain of OA. HA can also reduce OA-associated pain by decreasing PGE2 and bradykinin (BK) synthesis, as well as substance P [Reviewed in (42–44)]. Gotoh et al. (78) found that HA with a MW >40 kDa produced an analgesic effect, and HA of 860 and 2,300 kDa produced high and long-lasting analgesia by interacting with HA receptors. Findings also suggested that the larger the molecule of HA, the higher the affinity of HA receptors for binding. Since HA did not directly bind to BK receptors, then analgesic effects of HA appears to be brought on by the interaction of HA and HA receptors on or surrounding the free nerve endings that detect pain in the joint tissue. Gomis et al. (147) found that the elastoviscous properties of HA solutions are determining factors in reducing pain-eliciting nerve activity both in normal and in inflammed rat joints.
In an in vitro study, Sasaki et al. (180) demonstrated that the expression of MMP-1 and MMP-3 mRNAs were induced by IL-1β in human synovial cells, and were strongly downregulated by HA (10 or 1,000 μg/mL). HA may inhibit binding of IL-1β to its membrane bound receptor by covering the cell surface, thereby suppressing the production of MMPs. The study suggested that IA HA may rescue inflammed joints from bone and cartilage destruction by reducing the production of MMP-1 and MMP-3. Yasui et al. (183) reported suppression of IL-1α-induced PGE2 production in human synovial cells by HA in a dose- and MW-dependent manner. In another in vitro study, Maneiro et al. (175) investigated the effects of two HA formulations (Hyalgan®, 500–730 kDa HA, Bioibérica SA; and Synvisc®, hylan of 6,000 kDa, Biomatrix Inc.) on PGE2 and NO concentrations and in human OA chondroptosis. Results revealed that 500–730 kDa HA (200 μg/ml) decreased the synthesis of both IL-1-induced PGE2 and NO by 70 and 45%, respectively. Both HA preparations at 200 μg/mL decreased chondroptosis (40 and 36%, respectively). HA has also been reported to protect against hydroxyl (OH·) radicals generation (171). It has been demonstrated that by modulating rheological properties (such as viscoelasticity) of HA and SF by employing HA of selective MW or HA-derivatives, anti-inflammatory activity can be greatly improved (57).
Hsieh et al. (167) investigated the effects of HA with different MWs on the expression of the plasminogen activator (PA)/plasmin system, urokinase-type PA (u-PA), PA inhibitor-1 (PAI-1), and MMP-2 and MMP-9 in a series of chondral, meniscal, and synovial cultures of early development of OA. Higher-MW HA (Synvisc) provided the greatest ability to inhibit MMP-2, MMP-9, u-PA and PAI-1 expression. Findings clearly demonstrated that the therapeutic effects of using higher-MW HA to treat early OA may be partially dependent on downregulation of the PA/plasmin system and MMPs expression, which delay the structural progression of OA.
In contrast to findings discussed above, Asari et al. (148) reported that lower-MW HA can enhance or induce inflammation through Toll-like receptor 4 (TLR-4). However, oral administration of higher-MW HA (900 kDa) to MRL-lpr/lpr mice modulates Th-1-type autoimmune disease and inflammation by up-regulating SOCS3 expression and downregulating pleiotrophin expression via TLR-4.
Chondroprotective, Anti-chondroptotic, and Cartilage Repair Effect
The chondrocyte is the unique resident cell of articular cartilage, which is responsible for ECM composition, regulation, and homeostasis (110, 208). Normally, joint cartilage consists of 5% chondrocytes and 95% ECM. The ECM of articular cartilage is comprised of complex networks of proteins and glycoproteins, all of which are expressed by chondrocytes. In OA, chondrocytes serve as mechanosensors and osmosensors, and their metabolism is influenced by microenvironment that in return influences ECM composition, organization and ultimately the mechanical resilience of cartilage (110, 209, 210). As OA progresses, chondrocytes lose their ability to maintain cartilage homeostasis, as a result of decline in mitotic and synthetic activity, to respond to anabolic growth factors, and to synthesize cartilage-specific PG core proteins (CSPCP) (211).
In regard to cartilage repair, Kuroki et al. (154) suggested that IA administration of HA has a direct effect on chondrocytes or synoviocytes and the production of transforming growth factor (TGF)-β, basic fibroblast derived growth factor (FGF), and insulin-like growth factor (IGF)-1. Histological evidence suggests that HA prevents the degradation of cartilage and may promote its regeneration. Ghosh and Guidolin (25) also provided evidence that HA treatment mitigated synovial hypertrophy and increased the numbers of synovial fibroblast-like cells (FLC) while decreasing macrophages, lymphocytes, mast cells, and adipocytes. HA appears to provide cartilage protection by the downregulation of cytokines, free radicals, and proteolytic enzymes in synovial fluid.
In an early in vitro study, Palmoski and Brandt (212) reported that PGs aggregation in severely OA affected femoral cartilage was impaired and showed no interaction between PGs and HA. Fukuda et al. (172–174) reported a stimulatory effect of HA on PG synthesis and prevented cartilage degradation in IL-1-induced cartilage destruction, probably acting as a free-radical scavenger. However, inhibition of IL-1-induced superoxide anion by HA does not appear to interfere with binding of IL-1 to chondrocytes. Whether HA inhibits superoxide anion in a receptor-mediated fashion, as does CD44 (47), remains yet to be elucidated.
Bagga et al. (59) examined the effect of IA Hylan GF-20 injections on synovial fluid HA concentration, viscosity, and elasticity over a 6-months period in patients with mild to moderate OA of the knees. The findings suggested that HA viscosupplementation appears to promote endogenous HA production, since the concentrations and MW of native HA declines in OA (73, 75).
Takahashi et al. (67) assessed the effects of HA (0.3 mL, once a week for 5 weeks) on MMP-3, IL-1β, and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression in surgically-induced OA in New Zealand white rabbits. IL-1β is abundantly synthesized by OA synovium and cartilage (213), and induces the expression of MMP-3 (214) as well as PGE2 (215), and inhibits the formation of ECM (216). Takahashi et al. (67) suggested that one of the mechanisms of therapeutic effects of HA is down-regulation of MMP-3 (stromelysin) and IL-1β in synovium during early development of OA. TIMP-1 expression was not influenced by HA. In an in vitro study, using fluorescence microscopy, HA (800 kDa; 1 mg/mL) was shown to significantly suppress IL-1β-stimulated MMPs (MMP-1, MMP-3, and MMP-13) expression via CD44 surface receptor in human OA articular cartilage (51). Findings of this investigation revealed direct interaction between HA and CD44 receptor on chondrocytes.
In an in vitro study, Goto et al. (201) examined the effect of IL-1β on alpha2(VI) collagen gene in cultured rabbit articular chondrocytes and how this effect was reversed by HA. The chondrocytes cultured with IL-1β (1 and 10 ng/mL) showed significant decrease in alpha2(VI) collagen mRNA expression. However, the addition of both IL-1β and HA (1 mg/mL; MW 900–2,000 kDa) suppressed the reduced mRNA levels. Findings of this study suggested that suppression of transcriptional activity for type VI collagen appears to be associated with the reduction of cartilage matrix tissue and that HA is associated with the suppression of the effect of IL-1β. In another in vitro study, a hexadecylamide-derivative of HA (HYMOVIS®) provided better ameliorating effects than unmodified HA (MW 500–730 kDa) on human OA chondrocytes and synoviocytes, by inhibition of phosphorylation of the cell signaling molecules JNK, p38, and NF-κB.
In an in vitro study, Lisignoli et al. (202) isolated chondrocytes from human OA knee cartilage, and evaluated the effect of HA on both spontaneous and anti-Fas-induced apoptosis. HA (MW 500–730 kDa) at 1 mg/mL significantly reduced the anti-Fas-induced chondroptosis (by binding its specific receptors, CD44 and ICAM-1), but did not affect spontaneous chondroptosis.
From several other studies, it has also been suggested that HA inhibits: (1) IL-1β-induced MMPs activity in synovial fluid (68), (2) mRNA expression of proinflammatory cytokines, COX-2, and PGE2 production via interaction with CD44 receptors in subacromial synovial fibroblasts, (3) expression of ADAMTS4 (aggrecanase-1) in human OA chondrocytes (193), and (4) osteoclast differentiation via Toll-like receptor 4 (217).
Experimental Studies (Rat, Rabbit, and Sheep)
Rat
In the context of OA and ameliorating effects of HA, the rat has mainly been used as a model for pain assessment (218). In the rat model of knee pain reaction (in vivo), Gotoh et al. (78) investigated the mechanism of the analgesic effect of sodium HA. The simultaneous administration of PGE2 with bradykinin (BK) or hyaluronidase digestion of endogenous HA produced hyperalgesia in BK-induced knee pain. Results revealed that higher sensitivity to the pain reaction is induced in a diseased joint (higher PGE2 content, lower concentration and MW of HA in SF) than in a normal joint. Sodium HA definitely decreased BK-induced pain, and its analgesic effect was observed for a longer period, depending on its dose in pre-treatment and the degree of its distribution in synovial tissues. Gotoh et al. (78) suggested that increasing viscosity of SF by increasing HA concentration could decrease pain even without normalizing MW in the joint. Sodium HA seems to exert its analgesic effect by blocking pain receptors in synovial tissues and holding endogenous pain substances in its molecule. It can be suggested that the characteristic steric configurations of higher-MW HA are needed for the manifestation of the analgesic effect. Furthermore, HA did not directly bind to BK receptors, indicating that analgesia of HA appears to be brought on by the interaction of HA and HA receptors on or surrounding the free nerve endings that detect pain in the joint tissue.
Gomis et al. (147) examined the effects of three different preparations of HA on the sensitivity of nociceptors in the normal and the acutely inflammed rat joint. Findings indicated that viscoelasticity and MW are the determining factors in reducing pain-eliciting nerve activity both in normal and in inflammed rat joints. Findings also revealed that the greater the viscoelasticity of the preparation, the fewer repeat injections were needed for long-lasting pain relief. Aihara et al. (69) investigated mechanisms of sodium HA with different MWs in monosodium urate (MSU) crystal-induced arthritis and nociception in rats. Results suggested that in a MW- and dose-dependent manner, sodium HA-induced antinociceptive effect may be due to the inhibition of PGE2 and BK synthesis in the synovial joints, thereby resulting in an the graded abnormal gait. In regard to mechanism of action of HA viscosupplementation, Gomis et al. (147) proved that the exchange of pathologic fluid of low elastoviscosity and low HA concentration with a pure HA solution of high viscoelasticity and high concentration produced an immediate decrease in the concentration of pain-stimulating and inflammatory agents in the joint. Also, the injection of a high concentration (10–20 times > than normal) of higher-MW HA into an arthritic joint results in a nearly normal IA fluid. The injected HA flowed out of the joint in 5–7 days, but the analgesic effect persisted longer.
In an experimental study in rats, Campo et al. (177) induced arthritis by intradermal injections of 250 μg of bovine type II collagen in 125 μl of 0.1 M acetic acid emulsified in an equal volume of complete Freund's adjuvant. Rats received GAGs (HA and chondroitin sulfate) in a volume of 1 mL/kg body wt, ip/day until the 20th day. HA and chondroitin sulfate (CS) reduced lipid peroxidation, restored the endogenous antioxidants (reduced glutathione and superoxide dismutase), decreased plasma TNF-α levels, and limited synovial neutrophil infiltration. The study results suggested that collagen-induced erosive damage in arthritis may be due to free radicals and can be treated with the antioxidative properties of GAGs. GAGs also exhibited anti-inflammatory property in rat arthritis model.
Rabbit
In an in vitro study, Goto et al. (201) investigated how the type α2(VI) collagen gene is regulated by IL-1β in cultured rabbit articular chondrocytes. To investigate the effect of HA on this collagen mRNA expression by IL-1β, chondrocytes were exposed to IL-1β (10 ng/mL) in the presence of HA (0.01, 0.1, 1 mg/mL; MW of 900 kDa). Chondrocytes were also exposed to IL-1β (10 ng/mL) in the presence of HA (1 mg/mL) with MWs of 200, 900, and 2,000 kDa. Findings indicated that suppression of transcriptional activity of type VI collagen is associated with the reduction of cartilage matrix tissue, and that HA is associated with the suppression of the effect of IL-1β.
In a number of experimental OA studies, HA of different MWs have been evaluated for therapeutic efficacy and safety in rabbits. Kikuchi et al. (195) examined the effect of HA (0.1 mL/kg) with varying MW formulations [800,000 Da, HA80 (1%); or 1,900,000 Da, HA190 (0.01–1%)] on cartilage degeneration in surgically-induced rabbit model (partial meniscectomy) of OA. With HA190 (1%), there was dramatic inhibition of cartilage degeneration in both the femoral condyle and the tibial plateau, and the degree of protection was greater than with HA80. Scanning electron micrographs of femoral cartilage showed that cartilage degeneration was less severe with HA190 than with saline. Findings also suggested that IA administration of higher-MW HA is more effective than lower-MW HA in inhibiting cartilage degeneration in early OA. Researchers from the same group administered sodium HA (MW 2,020,000, HA202) into the right knee of mature rabbits with osteoarthrosis (ACLT model), and found that the cartilage degeneration and chondrocyte loss were less compared to rabbits treated with a formulation of HA95 (MW 950,000) and even greater than the control (saline) group (194). In another study, Shimizu et al. (196) injected IA HA of varying MW in surgically-induced OA New Zealand white rabbits, once a week for 5 weeks in one knee, using the other knee as a control. Histomorphometric analysis revealed that HA-treatment suppressed cartilage degeneration. However, biochemical analysis of synovium showed no significant difference between treated and control.
Using the ACLT model, Amiel et al. (219) investigated the long-term effects of single and repeated administration of HA (Hyalgan®) therapy on OA progression. Findings revealed that repeated HA injections reduced the degree of articular degeneration, and may be advantageous in the long-term management of OA. Mainil-Varlet et al. (220) evaluated therapeutic efficacy of HYADD® 4-G (a HA derivative) alone or in conjunction with growth factors. Results suggested that HYADD® 4-G delayed cartilage degeneration and that the association of HYADD® 4-G with growth factors was synergistic. IA HA has also been shown to act via several disease modifying mechanisms in OA cartilage and synovium, but the effect of HA on subchondral bone in patients with OA remains unclear (65).
In a rabbit model of OA (partial meniscectomy), Hashizume et al. (15) demonstrated that higher-MW HA inhibited PGE2 production, protected cartilage degeneration, and exerted an analgesic effect. In a mechanistic study on OA in New Zealand white rabbits, Zhou et al. (199) injected 0.3 mL sodium HA (1%) once a week for 5 weeks, 5 weeks post-ACLT. Eleven weeks post-surgery, the cartilage changes in medial femoral condyles revealed that the expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) mRNA in saline-treated rabbits was greater than in HA-treated rabbits. Since PPAR-γ is associated with the chondroptosis (221, 222), HA may provide anti-chondroptotic and a protective effect on articular cartilage degeneration by inhibiting PPAR-γ mRNA expression. This can be one of the therapeutic mechanisms of HA in OA.
Sheep
In a pharmacokinetic study, Fraser et al. (157) estimated the metabolic t of HA (27 h) in SF in sheep from the rate of appearance of 3H2O in plasma after injection of highly polymerized labeled HA. This material is substituted with 3H in its acetyl group and is rapidly and almost completely degraded in sheep and other species to yield 3H2O. The study indicated that mild acute inflammation can induce major changes in the metabolic turnover of SF HA. Mean SF volume in the normal sheep hock joint was estimated to be 1.54 mL, and the concentration and content of HA were 0.54 mg/mL and 0.84 mg, respectively.
Ghosh et al. (223) evaluated two IA HA preparations (MW 800,000, AHA; and MW 2,000,000, DHA) in ovine joints with early OA (surgically induced medial meniscectomy). Animals when injected IA with 1 mL (10 mg/mL) of either HA preparation once a week for 5 weeks beginning at 16 weeks after initiation of arthropathy. Meniscectomy of sheep stifle (knee) joints resulted in matrix changes indicative of early OA. Both HA preparations appeared to improve gait (Ground Force Plate analysis), suggesting decreased lameness. However, cartilage damage (radiographic evidence) with DHA was found to be higher than with AHA. In a similar study, Ghosh et al. (224) examined the effects of AHA and DHA on cartilage composition and PG metabolism. The cartilage was analyzed for collagen and PG content and differential extractability with guanidine hydrochloride (GuHCl) solutions. The release of 35S-PGs from the tibial cartilage of the DHA-treated animals was found to be higher than in the saline-treated group. The biosynthesis of 35S-PGs, determined in vitro, for cartilage derived from the medial compartment was generally lower than for the lateral regions of the meniscectomized joints. The biosynthetic activity was further reduced in joints injected with the two HA preparations, but DHA reduced 35S04 incorporation into PGs more than AHA. The authors concluded that reduced biosynthesis of 35S-PGs and secretion into media was a consequence of increased loading of joints in the HA-treated animals rather than a direct effect of these preparations on chondrocyte metabolism.
Clinical Studies
Canine
Most studies in dogs with HA have been carried out in the surgically (anterior cruciate ligament transection, ACLT)-induced OA model. ACLT produces metabolic, biochemical, biomechanical and morphological changes in articular cartilage of the unstable knee that are consistent with those of OA in humans (225–231). Following ACLT, OA is often characterized by marginal osteophytes, fibrillation, cartilage PG depletion, synovial inflammation, and joint effusion (232). In the ACLT-induced OA model, the structure of newly synthesized [35S]-PG and its turnover have been characterized (225, 228). Arthropathy may release soluble protein(s) from the synovium, which may cause synovial proliferation and excessive secretion of HA, in addition to the concentration of water content and uronic acid (a PG metabolite).
Smith et al. (233) investigated the effects of HA (MW 1,500,000 Da) in ACLT-induced OA in mongrel dogs (5 weekly injections beginning the day after surgery), and compared results with saline-treated dogs. The severity of pathological changes in OA was graded, and composition of the cartilage and extent of aggregation of PG synthesized in vitro by cartilage slices were determined. The size and number of osteophytes and the extent of fibrillation of the articular cartilage in the unstable knee of the dogs that had received HA injections were grossly indistinguishable from those in the dogs whose knee had been injected with saline. In the saline-treated group, some dogs exhibited mechanical damage in the central region of the medial femoral condyle (MFCc) with deep cartilage ulcer, which extended down to the underlying bone. Other dogs in this group exhibited only pitting and fibrillation of the cartilage at this site. Also, in OA cartilage from the saline-treated group, the mean concentration of uronic acid was 30–60% greater than that in the contralateral knee. In contrast, the concentration of uronic acid in OA cartilage from the HA-treated dogs was 10–30% lower than that in cartilage from the contralateral knee. The PG concentration of cartilage in the OA knee was significantly reduced, suggesting that HA therapy might adversely affect the biomechanical properties of the cartilage.
In surgically-induced OA in dogs, biochemical and morphological changes in cartilage and the effects of IA injections of HA have been evaluated (234, 235). Abatangelo et al. (235) and Schiavinato et al. (236) reported beneficial effects of HA on the cartilage in response to damage, and a clear-cut inhibitory effect on the development of the FLC layer on the cartilage in untreated joints was noted. Marshall et al. (146) reported that a series of 3 weekly injections of 0.5 ml (4 mg) of HA (MW 6,000,000 Da) ameliorated the severity of OA in dogs. In addition to its contribution to the structural properties of the ECM, HA may have a role in regulating the synthesis of PGs during maturation of articular cartilage and in repair processes (154).
Both in preclinical and clinical studies, Flex choice, a novel patent pending nutraceutical product developed by Clinic-Choice, which contains Flexpro MD (low-MW HA, pure krill oil, and astaxanthin) has clearly shown an anti-OA effects in dogs. Pak et al. (237) demonstrated that Flexpro MD markedly reduced phosphorylation of NF-κB p65 and inhibition of κB-α (IκB-α) induced by lipopolysaccharides (LPS). In addition, Flexpro MD displayed anti-inflammatory effects in mice against LPS-induced arthritis by significantly reducing the expression of pro-inflammatory cytokines and other inflammatory markers, thereby reducing pain.
Equine
Since the early 1970's, IA HA has commonly been used in the treatment of synovitis and OA (knee, carpal, and fetlock joints), and osteoarthrosis in racehorses and heavy work horses (238–241). HA can be injected directly into an affected joint. Auer et al. (242) reported that in naturally occurring and experimentally induced OA in horses, IA injection of HA (40 mg) significantly reduced lameness and increased weight bearing on the treated limb, measured using the Ground Force Plate (GFP). HA is especially indicated for mild to moderate levels of synovitis associated with equine OA. However, it has limitations in treating severe synovitis or OA.
In an earlier study, Rose (239) injected IA HA in 16 horses with osteoarthrosis of the carpus, fetlock, hock, and coffin joints. In 11 of those horses lameness was completely relieved. The other five horses showed less swelling of the joint capsule, and increased range of joint movement. Rydell et al. (71) injected HA in combination with methyl-prednisolone or methyl-prednisolone alone in the joints of track horses with traumatic arthritis, and found that the clinical response was considerably better than when the corticosteroid was used alone. Using GFP, Gingerich et al. (186, 243) demonstrated that IA administration of 20 or 40 mg HA (in a dose-dependent manner) in experimentally induced OA in horses produced significant functional improvement in joints, while 5 or 10 mg did not. In a clinical trial, Philips (165) compared the efficacy of IA sodium HA products (Synacid, Equron, Hyalovet, Hyvisc, and Hylatrin V) in horses. These products vary in method of production, MW, solvent, and packaging. The MWs of the various sodium HA products are: 150,000 Da for Synacid; 1,500,000–2,000,000 Da for Equron; 750,000–1,000,000 Da for Hyalovet; 2,100,000 Da for Hyvisc; and 3,500,000 Da for Hylatrin (81, 241). Findings of this and other studies suggested that: (1) more than one treatment might be helpful for all these products, and (2) the effect appears to be MW- and concentration-dependent (164, 241).
McIlwraith (161) reported that sodium HA may affect the composition of SF through steric exclusion of active plasma components and leucocytes from the joint cavity by modulating chemotactic response. These investigators also studied molecular interactions between HA and CD44 receptors (present on lymphocytes, neutrophils, and synoviocytes) in horses. Recently, Niemelä et al. (244) reported analgesic and pain reducing effects of IA non-animal stabilized HA (NASHA) in the treatment of lameness localized in the metacarpophalangeal joint in horses. 67% of NASHA (3 mL)-treated horses were able to perform normal exercise, and scores in the flexion test improved compared to the saline -treated placebo group.
During the last decade, the use of IV HA has become more common, especially for less localized OA disorders. However, there is only one licensed product, made by Bayer, named Legend® in the US, and Hyonate® elsewhere. It has been suggested that when HA is used in combination with corticosteroids, HA not only improves beneficial effects of corticosteroids, but it can placate the side effects of certain corticosteroids.
In several other studies, HA in different forms and formulations has been found effective in ameliorating OA and other forms of joint ailments by analgesic, antioxidative/antinitrosative, anti-inflammatory, and cartilage repair effects by multiple biological and pharmacological mechanisms (186, 243, 245–249).
According to Canadian regulations, HA in HY-5-preparation should not be administered to horses that are to be slaughtered for meat.
Humans
Currently, many formulations of HA are prepared with lower-MW (500–730 kDa), intermediate-MW (800–2,000 kDa), and higher-MW (~6,000 kDa) for IA injections and are available worldwide (250). Therapeutic efficacy of these products can differ based on HA origin, method of production, treatment schedule, MW, viscoelasticity and other rheological properties, half-life within the joint, and pharmacokinetics and pharmacodynamics. In general, the half-life of HA products in the joint is reported to be much shorter than their duration of clinical effect (251). Some of the FDA approved HA products include: Hyalgan (Fidia Pharma), Supartz (Bioventus), Orthovisc (DePuy Mitek), Euflexxa (Ferring Pharmaceuticals), Synvisc/Synvisc One (Sanofi-Aventis), and Gel-Syn (Institut Biochimique). In clinical studies, there is no evidence of the superiority of any one brand of viscosupplement over another brand. In general, patients below 65 years of age and those with less severe OA are likely to be benefited from HA viscosupplementation (252). Also, some clinical studies indicated that therapy with an IA HA formulation with a higher-MW (e.g., hylan G-F 20) was more effective in relieving OA-associated pain than therapies with lower-MWs (e.g., sodium hyaluronate) (142, 253–255).
In a large number of clinical trials, HA has been found to exhibit anti-OA effects. HA is a slow-acting anti-OA agent that can be used prophylactically or therapeutically as an anti-inflammatory symptom modifying and disease modifying agent (154, 156, 256–259). Evidence for disease-modifying activity of HA stems from: (1) the complex cellular and molecular effects of HA in the synovium and ECM of the articular cartilage, including interactions between exogenously administered HA and articular cartilage, subchondral bone, matrix PGs, and collagens; (2) the effects of HA administration in animal models of OA, including total or partial meniscectomy and ACLT; and (3) results of clinical trials using one HA, Hyalgan (sodium HA, MW 500–730 kDa) that evaluated structural outcomes, such as joint-space width, chondrocyte density and vitality, and arthroscopic evaluation of chondropathy (256). In a few clinical trials, IA injections of HA was found to inhibit joint space narrowing on X-ray images and slow the progression of cartilage degeneration in follow-up arthroscopy (260, 261).
Berenbaum et al. (250) found that treatment with an intermediate-MW (800–1,500 kDa) HA (GO-ON, Rottapharm) was significantly superior to lower-MW (500–730 kDa) HA (Hyalgan, Fidia Pharma) for knee OA symptoms. Findings revealed that a higher proportion of patients with treatment response was observed with GO-ON than with Hyalgan (73.3% vs. 58.4%). In a randomized, multicenter clinical trial, higher-MW HA (Orthovisc) was reported to be very effective and safe in the treatment of mild to severe knee OA. However, in other studies conducted with HA of different MW in knee OA patients, it has been concluded that higher MW HA preparations are not superior to intermediate- or lower-MW compounds (159, 262–267).
In a clinical study, oral administration of HA (200 mg/day) for 12 months improved the symptoms of knee OA in patients aged 70 years or younger when combined with quadriceps strengthening exercise (268). In another clinical trial, Nelson et al. (190) reported that oral intervention with HA (Oralvisc®) provided OA improvement. Findings revealed that the regulation of the inflammatory milieu detected both in serum and SF in the patients treated with an oral preparation has been associated with a trend toward a normalization of the HA turnover in SF. Furthermore, this partial normalization could suggest a slower OA progression since HA turnover has been associated with disease severity in preclinical models.
HA has been reported to produce some side effects, such as muscle pain, cramping, pain in the injected knee, and swelling in arms and legs making movement difficult (269).
HA in Wound Healing
Wound healing is a complicated multi-step process, which involves various cell functions, such as cell migration, proliferation, basement membrane regeneration, and the formation of granulation tissue. According to Weigel et al. (270), the wound itself is a transitory organ or structure whose function is to remodel, successively, a series of increasingly complex and ordered ECMs. Because of its high concentration in skin and mucosa, HA is reported to have important biological roles in skin or mucosal wound healing by influencing inflammation, granulation, and reepithelialization (7, 10, 38, 39, 271–275). The level of HA is reported to be high in granulation tissue during the wound healing process. Using immunohistochemical techniques, Picker et al. (276) localized epithelium-, leucocyte-, and fibroblast-specific CD44 receptors for HA binding. In normal connective tissue and granulation tissue, CD44 staining was restricted to cells, whereas HA was diffusely distributed throughout tissues. In normal mucosa, CD44 was localized in all layers of the stratifying epithelium except for stratum corneum, and throughout the connective tissue. Electron microscopic examination of the basal and spinous cell layers displayed HA, both associated with the cell surface and free in the intercellular space. Oksala et al. (272) found that HA and CD44 were localized in the same region of the epithelium (around mucosal keratinocytes) in all stages of wound healing. Wang et al. (277) also noted that in the keratinizing skin epithelia both HA and CD44 receptor showed an intense staining with a close co-distribution. Kaya et al. (278) reported that the two major functions of CD44 receptors in skin may be the regulation of keratinocyte proliferation in response to extracellular stimuli and the maintenance of local HA homeostasis.
Oksala et al. (272) investigated the expression of PGs and HA during healing of human mucosal wounds. Findings revealed that CD44 surrounded migrating keratinocytes at all stages of wound healing. In epithelium, CD44 and HA remarkably localized to the same region. Expression of syndecan-1 was switched from the suprabasal cell layer of unwounded epithelium to the basal cell layer of the migrating wound epithelium. The area under the wound epithelium containing newly synthesized collagen fibers first became positive for decorin on day 7, where staining for biglycan was negative. Granulation tissue was also strongly positive for CD44 and HA. Migrating keratinocytes expressed both CD44 and syndecan-1. During differentiation of keratinocytes, expression of CD44 preceded that of syndecan-1. Binding of HA is probably not the only function of CD44 in keratinocytes. CD44 is a multifunctional cell surface PG that binds high endothelial venue ligand, HA, fibronectin, laminin, and collagens (272). The study concluded that different basement membrane-associated heparin sulfate proteoglycan (BM-HSPG) have multiple functions in keratinocyte migration and differentiation during reepithelialization.
In an interaction study, Weigel et al. (279) proposed that fibrin and HA are macromolecular regulators during inflammation and wound healing. These authors found significant binding of 125I[HA] with human, sheep, rabbit, dog, baboon, goat and pig fibrinogens, and no interaction with horse, rat, or cow fibrinogens. HA and fibrin have organizational, structural and regulatory functions (at both the molecular and cellular level) at different times during the wound healing process by exerting anti-inflammatory activity and new blood vessel formation (274, 280). Aya and Stern (281) reported that levels of higher MWHA are more prominent in the earliest stages of wound repair. However, in a number of experimental studies, higher-MW HA has been shown to inhibit angiogenesis, and lower-MW HA has been shown to promote angiogenesis (39, 282–284). The higher MW-HA polymers suppress angiogenesis with their ability to inhibit early response genes, such as c-fos, c-jun, and Krox-20 in endothelial cells (285). Findings revealed that fibrin is a common component of the normal ECM and fibrin and fibrinogen specifically interact with HA. The early appearance of higher-MW HA and the later appearance of lower-MW HA at the wound site as it is degraded provides a mechanism to regulate and integrate the timing of the cellular activities needed to initiate and sustain the inflammatory response and the wound healing process (270, 286). This study also emphasized that thrombin-induced formation of fibrin clots is also affected by HA, which decreases the lag time before clotting and increases the rate of clot formation. It is noteworthy that an increase in circulating HA levels could adversely affect hemostasis and increase the risk of thrombosis or bleeding.
In conclusion, the wound healing process can be organized into three main events, and each event involves HA: (1) a matrix rich in HA is laid down in a cell-poor space, (2) mesenchymal cell migration is stimulated and the HA matrix is infiltrated by cells migrating from the adjacent tissues, and (3) cells within the HA matrix secrete both hyaluronidase, which degrades the HA, and sulfated GAGs and collagen, which concomitantly replace the HA and the matrix is remodeled (270, 281, 287).
HA in Ophthalmic Conditions
The use of HA has been implicated in various ophthalmic conditions, including keratoconjuctivitis sicca (KCS) or dry eye disease (DED) in humans and animals (9, 10, 288–293). HA solutions (0.1% HA) effectively lubricate the ocular surface and are used for the relief of dry eye related symptoms (294). However, HA undergoes rapid clearance due to limited adhesion, which necessitates frequent instillation. Furthermore, highly viscous artificial tear formulations with HA blur vision and interfere with blinking. Lee et al. (294) synthesized a heterobifunctional polymer-peptide system with one end binding HA while the other end binds either sialic acid-containing glycosylated transmembrane molecules on the ocular surface epithelium, or type I collagen molecule within the tissue matrix. These investigators treated rabbit ocular surface tissues with binding peptides and HA solutions and demonstrated superior lubricating with long-lasting effect, and reduced kinetic friction coefficients compared to tissues treated with conventional HA solution. HA ameliorates the symptoms of DED by reducing irritation, and by moisturizing the eye, enhancing tear film stabilization, reducing friction during blinking, preventing binding of harmful substances to the eye, and replenishing the deficiencies of sodium HA in the tear film (293, 295). In a number of studies, HA has been shown to improve healing of corneal epithelial abrasion and wounds (296–302). Currently, Remend® (a product of Bayer) containing 0.4% Hyasant-S (a cross-linked, modified HA) is available to maintain lubrication and hydration of the eye in DED in dogs and cats.
HA plays an important role in ophthalmic surgery during operations of the anterior segment of the eye, such as trabeculectomy, cataract removal, glaucoma treatments, refractive surgery, and corneal plastic surgery (293). Due to its viscoelastic, lubricating, cushioning, hydrating, and other rheological properties, HA has been shown to facilitate tissue healing (such as corneal epithelium cell proliferation, cell migration, retinal reattachment, etc) following ophthalmological surgery (288, 293, 296, 299, 303–305). HA exerts its effects through the stabilization of the tear film, decreased duration of healing, minimized risk of adhesions, decreased formation of free radicals, and normalization of intra-ocular pressure. Taken together, HA appears to play significant roles in health and diseases of eye.
HA in Chemoprevention and Cancer Therapy
In animal and cell models, HA has been implicated in tumor progression, and it has been reported to have a profound impact on several signaling pathways involved in cancer (10, 306, 307). The effects of HA are mostly mediated by interactions with cell surface receptors (CD44, RHAMM, LYVE, and TLR-2 and TLR-4) that, when activated, bind and respond to HA (308, 309). HA is the primary ligand for CD44 that is overexpressed in many cancer types including pancreatic, breast, lung, ovarian, prostate, etc (307, 308, 310–316). Members of the CD44 family of transmembrane glycoproteins emerge as major signal transduction control units (317). CD44 isoforms participate in several signaling pathways ranging from growth factor-induced signaling to Wnt-regulated pathways. The role of CD44 family members in tumor progression and metastasis is most likely linked to the function of the various isoforms as signaling hubs. Increasing evidence suggests that these proteins are directly involved in tumor and metastasis initiation. Since HA influences oncogenic signaling pathways, researchers found efficacious methods of inhibiting HA-receptor interactions in a manner that interferes with tumor progression. Treatment with small oligomers of HA that compete for constitutive binding of polymeric HA to its endogenous receptors appears to be one of the approaches. The hypothesis underlying this approach is that signal transduction by endogenous HA is dependent on high affinity, multivalent interaction with receptors and that small oligomers that bind monovalently will act as antagonists by replacing multivalent and cooperative interactions with low affinity, low valency receptor interactions. It has been reported that HA composed of 6–18 sugar residues binds monovalently to CD44, whereas larger polymers bind multivalently (318). Yang et al. (55) reported that native high MW HA (nHA) binding to CD44 selectively induces CD44 clustering, which could be inhibited by oligosaccharides of hyaluronan (oHA). Findings also revealed that HA regulates cell adhesion in a manner specifically dependent on its MW. oHA promoted cell adhesion, while nHA showed no effects.
HA-receptor interactions influence the activity of several signaling pathway components, including those that promote cell growth, survival, and motility, e.g., ErbB2/ErbB3, Ras, Erk, Src, NFκB, and phosphoinositide 3-kinase, depending on the type and physiological state of cells (306). These investigators have also shown that HA constitutively regulates activation of several receptor tyrosine kinases, such as ErbB2, EGFR, PDGFR, IGFR and c-MET, which are known to be important in progression of various cancer types. These events can lead to inhibition of downstream cell survival and proliferation pathways, e.g., phosphoinositide 3-kinase activity and phosphorylation of Erk, Akt, GSK3, BAD and FKHR (319, 320). HA oligomers competitively block binding of endogenous HA polymer to CD44, consequently giving rise to attenuated signaling. Misra et al. (321) showed that both constitutive activation of ErbB2 and ligand-mediated activation of IGF1R-β and PDGFR-β are reversed by co-treatment of the cancer (colon, prostate, and breast) cells with a HA antagonist, and concluded that HA serves a general function in receptor tyrosine kinase (RTK) activation.
The conjugation of a drug to HA can confer specificity and selectivity for cancerous cells, and can also provide a pharmacological advantage in terms of solubilization and stabilization. Montagner et al. (307) evaluated the efficacy of a loco-regional intraperitoneal treatment with a bioconjugate of HA (ONCOFID-S) delivered by chemical linking of SN-38, the active metabolite of irinotecan (CPT-11), to HA in a mouse model of ovarian carcinogenesis. Findings revealed that SN-38 conjugation to HA significantly improved the profile of in vivo tolerability and enhanced therapeutic efficacy for ovarian cancer treatment. In vitro results suggested that the conjugate selectively interacted with ovarian cancer cells through the CD44 receptor, disclosed a dose-dependent tumor growth inhibition efficacy comparable to that of SN-38 drug, and inhibited topoisomerase I function leading to apoptosis by a mechanism involving caspase-3 and−7 activation and PARP cleavage. Studies have also demonstrated that a derivative of HA and different types of HA-paclitaxel conjugates have a greater potential as anticancer therapies (322–325).
Taken together, the use of HA alone or in combination with established agents (doxorubicin, taxol, vincristine, methotrexate, imatinib, gemcitabine, cisplatin, 5-fluorouracel, etc.) seems to be a promising new avenue for anticancer therapeutics (306, 326–329).
Toxicity and Safety Evaluation
HA, being a physiological component, is not expected to produce adverse reactions even after repeated administration (66, 330). In a large number of clinical trials, HA has been found to be safe and well-tolerated in OA patients, when given IA (107, 166, 251, 331–334). A number of studies concluded that lower-MW, intermediate-MW, and higher-MW HA are clinically safe and well-tolerated (159, 262–267).
Maheu et al. (159) observed 470 adverse events reported by 123 patients (88.5%) in the F60027 (Structovial®) group; and 492 adverse events reported by 122 patients (87.1%) in the Hylan G-F-20 (Synvisc®) group. A total of 102 treatment emergent adverse events (TEAE) were reported by 56 patients (40.3%) in the F60027 group and 120 TEAE were reported by 60 patients (42.3%) in the Hylan G-F20 group. In this investigation, six serious adverse events (SAE) were reported by 6 patients, 1 in the F60027 group and 5 in the Hylan group. Following IA injections, tolerance of HA was found to be satisfactory (1 in the F60027 group and 5 in the Hylan group).
Following IA HA administration, some minor side effects may occur, such as pain at the injection site (in 1–30% of patients), local joint pain and swelling (in 1–30%), and local skin reactions (in 3–21%) (106). Also, some forms of HA may cause these adverse effects more frequently than others. These effects are transient. In rare cases, treated joints may become infected (335).
Contraindications
HA treatment is contraindicated in individuals who are hypersensitive to HA products, woman who are pregnant or nursing, pediatric patients, patients with bacteremia, or patients with infections in or around the target knee (106). Also, patients with liver or kidney diseases or Shar-pei dogs should not receive HA parenterally, as high circulatory HA levels may cause thrombosis.
Concluding Remarks and Future Perspective
HA is a naturally occurring non-sulfated GAG produced in many body organs and tissues. HA is also produced by microbial fermentation. The applications of HA depend on its rheological properties (such as MW, viscoelasticity, etc) and therefore quality products are prepared having HA of specific MWs. HA has been considered to be a stealth molecule for joint health, as it plays multiple roles including: articular cartilage lubrication, antioxidative/antinitrosative, analgesic, anti-inflammatory, chondroprotective, prevent ECM degradation, and cartilage repair effects. HA exerts anti-OA effect by interacting with receptors, enzymes, and many other biomolecules. All these physicochemical and biological properties of HA appear to be MW-dependent. Thus, a rationale for HA in the use of OA or skin conditions exists. Future studies need to identify uses of HA in health conditions other than OA, and clarify the relevance of its MW, and long-term clinical trials in canine and equine.
Author Contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Conflict of Interest Statement
RL and AjS are employees of Vets Plus Inc.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The authors would like to thank Ms. Denise M. Gupta for her technical assistance in preparation of this manuscript.
Abbreviations
ACLT, anterior cruciate ligament transection; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; BK, bradykinin; MB-HSPG, basement membrane-associated heparan sulfate proteoglycan; cAMP, cyclic adenosine monophosphate; COX-2, cyclooxygenase-2; CSPCP, cartilage-specific PG core proteins; ECM, extracellular matrix; FDA, Food and Drug Administration; FLC, fibroblast-like cells; FLS, fibroblast-like synoviocytes; GAG, glycosaminoglycan; GSH, reduced glutathione; HA, hyaluronic acid/hyaluronan; HARE, hyaluronic acid receptor for endocytosis; HAS, hyaluronan synthase; IA, intra-articular; ICAM1, Inetercellular adhesion molecule 1; IGF, insulin-like growth factor; IL-1β, interleukin-1β; iNOS, inducible nitric oxide synthase; IV, intravenous; kDa, kilo Dalton; LYVE-1, lymphatic vessel endothelial hyaluronan receptor-1; MFCc, medial femoral condyle; MMP, matrix metalloproteinase; MSU, monosodium urate; MW, molecular weight; NASHA, non-animal stabilized HA; NF-κB, nuclear factor-kappaB; NO, nitric oxide; OA, oateoarthritis; PA, plasminogen activator; t-PA, tissue-type plasminogen activator; uPA, urokinase-plasminogen activator; PG, proteoglycan; PGE2, prostaglandin E2; PPAR-γ, peroxisome proliferator activated receptor-γ; RANTES, regulated on activation, normal T cell expressed and secreted; RHAMM, receptor for hyaluronate-mediated motility; RNS, reactive nitrogen species; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; SAE, serious adverse events; SF, synovial fluid; SOD, superoxide dismutase; TEAE, treatment emergent adverse events; TGF-β, transforming growth factor β; TIMP-1, tissue inhibitor of metalloproteinase-1; TLR, toll-like receptor; TNF-α, tumor necrosis factor-alpha; TRAIL, TNF-related apoptosis-inducing ligand; TSG6, tumor-stimulated gene 6.
References
1. Sugahara K, Schwartz NB, Dorfman A. Biosynthesis of hyaluronic acid by Streptococcus. J Biol Chem. (1979) 254:6252–61.
2. Yu HM, Stephanopoulos G. Metabolic engineering of Escherichia coli for biosynthesis of hyaluronic acid. Metab Eng. (2008) 10:24–32. doi: 10.1016/j.ymben.2007.09.001
3. Liu L, Liu Y, Li J, Du G, Chen J. Microbial production of hyaluronic acid: current state, challenges and perspectives. Microb Cell Fact. (2011) 10:99. doi: 10.1186/1475-2859-10-99
4. Chen WY, Marcellin E, Hung J, Nielsen LK. Hyaluronan molecular weight is controlled by UDP-N-acetylglucosamine concentration in Streptococcus zooepidemicus. J Biol Chem. (2009) 284:18007–14. doi: 10.1074/jbc.M109.011999
5. Maclennan AP. The production of capsules, hyaluronic acid and hyaluronidase to 25 strains of Group C Streptococci. J Gen Microbiol. (1956) 15:485–91. doi: 10.1099/00221287-15-3-485
6. Prehm P. Release of hyaluronate from eukaryotic cells. Biochem J. (1990) 267:185–9. doi: 10.1042/bj2670185
7. Chen YWJ, Abatangelo G. Functions of hyaluronan in wound repair. Wound Rep Reg. (1999) 7:79–89. doi: 10.1046/j.1524-475X.1999.00079.x
8. Liang J, Jiang D, Noble PW. Hyaluronan as a therapeutic target in human diseases. Adv Drug Deliv Rev. (2016) 97:186–203. doi: 10.1016/j.addr.2015.10.017
9. Fallacara A, Vertuani S, Panozzo G, Pecorelli A, Valacchi G, Manfredini S. Novel artificial tears containing cross-linked hyaluronic acid: an in vitro re-epithelialization study. Molecules. (2017) 22:2104. doi: 10.3390/molecules22122104
10. Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the Third Millennium. Polymers. (2018) 10:701. doi: 10.3390/polym10070701
11. Balazs EA. Sodium hyaluronate and joint function. JEVS. (1985) 5:217–28. doi: 10.1016/S0737-0806(85)80102-7
12. Balasz EA, Laurent TC. New applications for hyaluronan. In: Laurent TC, editor. The Chemistry, Biology, and Medical Applications of Hyaluronan and its Derivatives. London: Portland Press (1998) p. 325–36.
13. Ghosh P. The role of hyaluronic acid. (hyaluronan) in health and disease: Interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheumatol. (1994) 12:75–82.
14. Moreland LW. Intra-articular hyaluronan. (hyaluronic acid) and hyalans for the treatment of osteoarthritis: mechanism of action. Arthr Res Ther. (2003) 5:54–67. doi: 10.1186/ar623
15. Hashizume M, Koike N, Yoshida H, Suzuki M, Mihara M. High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis. Mol Rheumatol. (2010) 20:432–8. doi: 10.1007/s10165-010-0299-1
16. Necas J, Bartosicova L, Brauner P, Kolar J. Hyaluronic acid. (hyaluronan): a review. Vet Med. (2008) 8:397–411. doi: 10.17221/1930-VETMED
17. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. (2011) 91:221–64. doi: 10.1152/physrev.00052.2009
18. Dahiya P, Kamal R. Hyaluronic acid: a boon in periodontal therapy. N Am J Med Sci. (2013) 5:309–15. doi: 10.4103/1947-2714.112473
19. Eurlings IM, Dentener MA, Mercken EM, de Cabo R, Bracke KR, Vernooy JH, et al. A comparative study of matrix remodeling in chronic models for COPD; mechanistic insights into the role of TNF-alpha. Am J Physiol Lung Cell Mol Physiol. (2014) 307:L557–65. doi: 10.1152/ajplung.00116.2014
20. Groβ D, Childs M, Piaton JM. Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjuctivitis. Clin Opthalmol. (2017) 11:631–8. doi: 10.2147/OPTH.S131384
21. Turino GM, Ma S, Lin YY, Cantor JO. The therapeutic potential of hyaluronan in COPD. Chest. (2017) 153:792–8. doi: 10.1016/j.chest.2017.12.016
22. Kim JH, Moon MJ, Kim DY, Heo SH, Jeong YY. Hyaluronic acid-based nanomaterials for cancer therapy. Polymers. (2018) 10:1133. doi: 10.3390/polym10101133
23. Laurent TC, Laurent UBG, Fraser JRE. The structure and function of hyaluronan: an overview. Immun Cell Biol. (1996) 74:A1–7. doi: 10.1038/icb.1996.32
24. Laurent TC. The Chemistry, Biology and Medical Applications of Hyaluronan and Its Derivatives. London: Portland Press (1998).
25. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis; are the effects molecular weight dependent? Sem Arthr Rheum. (2002) 32:10–37. doi: 10.1053/sarh.2002.33720
26. Dechert TA, Ducale AE, Ward SI, Yager DR. Hyaluronan in human acute and chronic dermal wounds. Wound Rep Regener. (2006) 14:252–8. doi: 10.1111/j.1743-6109.2006.00119.x
27. Conrozier T, Chevalier X. Long-term experience with hylan GF-20 in the treatment of knee osteoarthritis. Expert Opin Pharmacother. (2008) 9:1797–804. doi: 10.1517/14656566.9.10.1797
28. Ström A, Larsson A, Okay O. Preparation and physical properties of hyaluronic acid-based cryogels. J Appl Polym Sci. (2015) 132:42194. doi: 10.1002/app.42194
29. Fraser JRE, Laurent TC, Laurent UB. Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med. (1997) 242:27–32. doi: 10.1046/j.1365-2796.1997.00170.x
30. Stern R. Hyaluronan catabolism: A new metabolic pathway. Eur J Cell Biol. (2004) 83:317–25. doi: 10.1078/0171-9335-00392
31. McCourt PA. How does the hyaluronan scrap-yard operate? Matrix Biol. (1999) 18:427–32. doi: 10.1016/S0945-053X(99)00045-1
32. Juhlin I. Hyaluronan in skin. J Intern Med. (1997) 242:61–6. doi: 10.1046/j.1365-2796.1997.00175.x
33. Hamerman D, Schuster H. Hyaluronate in normal human synovial fluid. J Clin Invest. (1954) 37:57–64. doi: 10.1172/JCI103585
35. Weismann B, Meyer K. The structure of hyaluronic acid and of hyaluronic acid from umbilical cord. J Am Chem Soc. (1954) 76:1753–7. doi: 10.1021/ja01636a010
36. Toole BP. Hyaluronan in morphogenesis. J Intern Med. (1997) 242:35–40. doi: 10.1046/j.1365-2796.1997.00171.x
37. Lee JY, Spicer AP. Hyaluronan: a multifunctional, mega-Dalton, stealth molecule. Curr Opin Cell Biol. (2000) 12:581–6. doi: 10.1016/S0955-0674(00)00135-6
38. Frenkel JS. The role of hyaluronan in wound healing. Int Wound J. (2014) 11:159–63. doi: 10.1111/j.1742-481X.2012.01057.x
39. Litwiniuk M, Krejner A, Speyrer MS, Gauto AR, Grzela T. Hyaluronic acid in inflammation and tissue regeneration. Wounds. (2016) 28:78–88. Available online at: http://www.woundresearch.com
40. Csoka AB, Stern R. Hypotheses on the evolution of hyaluronan: a highly ironic acid. Glycobiology. (2013) 23:398–411. doi: 10.1093/glycob/cws218
41. Holmes MWA, Bayliss MT, Muir H. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J. (1988) 250:435–41. doi: 10.1042/bj2500435
42. Gupta RC. Nutraceuticals in arthritis. In: Gupta RC, editor. Nutraceuticals: Efficacy, Safety and Toxicity. Amsterdam: Academic Press/Elsevier, (2016), p. 161–76.
43. Gupta RC, Srivastava A, Lall R, Sinha A. Osteoarthritis biomarkers. In: Gupta RC, editor. Biomarkers in Toxicology, 2nd edn. Amsterdam: Academic Press (2019) p. 929–43.
44. Gupta RC, Doss RB, Lall R, Srivastava A, Sinha A. Nutraceuticals in arthritis. In: Gupta RC, Srivastava A, Lall R, editors. Nutraceuticals in Veterinary Medicine. Cham: Springer Nature (2019), p. 365–85.
45. Sommarin Y, Heinegård D. Specific interaction between cartilage proteoglycans and hyaluronic acid at the chondrocyte cell surface. Biochem J. (1983) 214:777–84. doi: 10.1042/bj2140777
46. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan. (HA). receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem. (2001) 276:36770–8. doi: 10.1074/jbc.M102273200
47. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. (1990) 61:1303–10. doi: 10.1016/0092-8674(90)90694-A
48. Miyake K, Underhill CB, Lesley J, Kincade PW. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med. (1990) 172:69–75. doi: 10.1084/jem.172.1.69
49. Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol. (2002) 34:718–21. doi: 10.1016/S1357-2725(01)00166-2
50. Shimizu M, Yasuda T, Nakagawa T, Yamashita E, Julovi AM, Hiramitsu T, et al. Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol. (2003):1164–72. Available online at: http://www.researchgate.net
51. Julovi SM, Yasuda T, Shimizu M, Hiramitsu T, Nakamura T. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthr Rheum. (2004) 50:516–25. doi: 10.1002/art.20004
52. Entwistle J, Hall CL, Turley EA. HA receptors: regulators of signaling to the cytoskeleton. J Cell Biochem. (1996) 61:569–77. doi: 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B
53. Zaman A, Cui Z, Foley JP, Zhao H, Grimm PC, Delisser HM, et al. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am J Respir Cell Mol Biol. (2005) 33:447–54. doi: 10.1165/rcmb.2004-0333OC
54. Knudson CB, Knudson W. Hyaluronan and CD44: modulators of chondrocyte metabolism. Clin Orthop Relat Res. (2004) 427(Suppl.):152–62. doi: 10.1097/01.blo.0000143804.26638.82
55. Yang C, Cao M, Liu H, He Y, Xu J, Du Y, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. (2012) 287:43094–107. doi: 10.1074/jbc.M112.349209
56. Bhattacharya D, Svechkarev D, Souchek JJ, Hill TK, Taylor MA, Natarajan A, et al. Impact of structurally modifying hyaluronic acid on CD44 interaction. J Mater Chem B. (2017) 5:8183–92. doi: 10.1039/C7TB01895A
57. Chernos M, Grecov D, Kwok E, Bebe S, Babsola O, Anastassiades T, et al. Rheological study of hyaluronic acid derivatives. Biomed Eng Lett. (2017) 7:17–24. doi: 10.1007/s13534-017-0010-y
58. George E. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis. (1998) 57:637–40. doi: 10.1136/ard.57.11.637
59. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. (2006) 33:946–50. Available online at: http://www.synviscone.com.ar
60. Yasuda T. Progress of research in osteoarthritis: pharmacological effects of hyaluronan. Clin Calcium. (2009) 19:644–52.
61. Volpi N, Schiller J, Stern RS, Soltes L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem. (2009) 16:1718–45. doi: 10.2174/092986709788186138
62. Oe M, Tashiro T, Yoshida H, Nishiyama H, Masuda Y, Maruyama K, et al. Oral hyaluronan relieves knee pain: a review. Nutr Res. (2016) 15:11. doi: 10.1186/s12937-016-0128-2
63. Ogston AG, Stanier JE. The physiological function of hyaluronic acid in synovial fluid; viscous, elastic, and lubricant properties. J Physiol. (1953) 119:244–52. doi: 10.1113/jphysiol.1953.sp004842
64. Tamer TM. Hyaluronan and synovial joint: function, distribution and healing. Interdiscipl Toxicol. (2013) 6:111–25. doi: 10.2478/intox-2013-0019
65. Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. J Orthop Res. (2001) 19:500–3. doi: 10.1016/S0736-0266(00)90024-X
66. Migliore A, Giovannangeli F, Granata M, Laganá B. Hylan g-f 20: review of its safety and efficacy in the management of joint pain in osteoarthritis. Clin Med Insights Arthr Musculoskelet Disord. (2010) 20:55–68. doi: 10.1177/117954411000300001
67. Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D. The effect of hyaluronan on matrix metalloproteinase-3. (MMP-3), interleukin-1beta. (IL-1beta), and tissue inhibitor of metalloproteinase-1. (TIMP-1). gene expression during the development of osteoarthritis. Osteoarthr Cartil. (1999) 7:182–90. doi: 10.1053/joca.1998.0207
68. Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res. (2007) 465:241–8. doi: 10.1097/BLO.0b013e31815873f9
69. Aihara S, Murakami N, Ishii R, Kariya K, Azuma Y, Hamada K, et al. Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Nippon Yakurigaku Zasshi. (1992) 100:359–65. doi: 10.1254/fpj.100.359
70. Termeer C, Sleeman JP, Simon JC. Hyaluronan-magic glue for the regulation of the immune response? Trends Immunol. (2003) 24:112–4. doi: 10.1016/S1471-4906(03)00029-2
71. Rydell NW, Butler J, Balazs EA. Hyaluronic acid in synovial fluid. VI Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of arthritis in track horses. Acta Vet Scand. (1970) 11:139–55.
72. Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joint. Pathol Biol. (1974) 22:731–6.
73. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol. (1993) 39:3–9.
74. Borzachhiello A, Mayol L, Schiavinato A, Ambrosio L. Effect of hyaluronic acid amide derivative on equine synovial fluid viscoelasticity. J Biomed Mater Res A. (2010) 92:1162–70. doi: 10.1002/jbm.a.32455
75. Balazs E, Watson D, Ivan F. Hyaluronic acid in synovial fluid. I Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthr Rheum. (1967) 10:357–74. doi: 10.1002/art.1780100407
76. Rydell N, Balazs EA. Effect of intraarticular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clin Orthop Rel Res. (1971) 80:25–32. doi: 10.1097/00003086-197110000-00006
77. Gigis I, Fotiadis E, Nenopoulos A, Tsitas K, Hatzokos I. Comparison of two different molecular weight intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis. Hippokratia. (2016) 29:26–31. Available online at: http://www.artosyal.it
78. Gotoh S, Onaya JI, Abe M, Miyazaki K, Hamai A, Horie K, et al. Effects of molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. (1993) 52:817–22. doi: 10.1136/ard.52.11.817
79. Cyphert JM, Trempus CS, Garantziotis S. Size matters: molecular weight specificity of hyaluronan effects in cell biology. Int J Cell Biol. (2015) 2015:563818. doi: 10.1155/2015/563818
80. Knudson W, Ishizuka S, Terabe K, Askew EB, Knudson CB. The pericellular hyaluronan of articular chondrocytes. Matric Biol. (2018) 78–79:32–46. doi: 10.1016/j.matbio.2018.02.005
81. Aviad AD, Houpt JB. The molecular weight of therapeutic hyaluronan. (sodium hyaluronate): How significant it is? J Rheumatol. (1993) 21:297–301.
82. Balogh L, Polyak A, Mathe D, Kiraly R, Thuroczy J, Terez M, et al. Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs. J Agr Food Chem. (2008) 56:10582–93. doi: 10.1021/jf8017029
84. Liu N. Metabolism of macromolecules in tissue. Lymphat Res Biol. (2003) 1:67–70. doi: 10.1089/15396850360495718
85. Liu N. Trafficking of hyaluronan in the interstitium and its possible implications. Lymphology. (2004) 37:6–14. Available online at: http://www.u.arizona.edu
86. Fraser JRE, Laurent TC, Pertoft H. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J. (1981) 200:415–24. doi: 10.1042/bj2000415
87. Fraser JRE, Kimpton WG, Laurent TC, Cahill RN, Vakakis N. Uptake of hyaluronan in lymphatic tissue. Biochem J. (1988) 256:153–8. doi: 10.1042/bj2560153
88. Laurent UBG, Dahl LB, Reed RK. Catabolism of hyaluronan in rabbit skin takes place locally in lymph nodes and liver. Exp Physiol. (1991) 76:695–703. doi: 10.1113/expphysiol.1991.sp003536
89. Svanovsky E, Velebny V, Laznickova A, Laznicek M. The effect of molecular weight on the biodistribution of hyaluronic acid radiolabeled with 111In after intravenous administration to rats. Eur J Drug Metab Pharmacokinet. (2008) 33:149–57. doi: 10.1007/BF03191112
90. Eriksson S, Fraser JRE, Laurent TC, Pertoft H, Smedsrod B. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res. (1983) 144:223–8. doi: 10.1016/0014-4827(83)90458-5
91. Engström-Laurent A, Hellström S. The role of liver and kidneys in the removal of circulating hyaluronan. An experimental study in the rat. Connect Tiss Res. (1990) 24:219–24. doi: 10.3109/03008209009152150
92. Breborowicz A, Moberly JB, Pawlaczyk K, Polubinska A, Kuzlan-Pawlaczyk M, Wieczorowska-Tobis K, et al. Effects of hyaluronan used as a supplement in peritoneal dialysis solutions. In: Kennedy JF, Phillips GO, Williams PA, Hascall VC, editors. Hyaluronan, Vol 2. Biomedical, Medical and Clinical Aspects. Cambridge: Woodhead Publ Unlimited, (2002) p. 453–460.
93. Pierce SW. Efficacy of orally administered sodium hyaluronate gel in the racing thoroughbred. In: Balazs EA, Hascall VC, editors. Hyaluronan 2003 Proceedings. Chapter 6. Musculoskeletal System. Cleveland, OH: Matrix Biology Institute, (2004) p. 1–4.
94. Fraser JRE, Laurent TC, Engström-Laurent A, Laurent UGB. Elimination of hyaluronic acid from the bloodstream in the human. Clin Exp Pharm Physiol. (1984) 11:17–25. doi: 10.1111/j.1440-1681.1984.tb00235.x
95. Reed RK, Laurent UB, Fraser JR, Laurent TC. Removal rate of [3H] hyaluronan injected subcutaneously in rabbits. Am J Physiol. (1990) 259(Pt 2):532–535. doi: 10.1152/ajpheart.1990.259.2.H532
96. Stern R, Kogan G, Jedrzejas M, Šoltés J. The many ways to cleave hyaluronan. Biotechnol Adv. (2007) 25:537–57. doi: 10.1016/j.biotechadv.2007.07.001
97. Lepperdinger G, Strobl B, Kreil G. HYAL2, and the human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem. (1998) 273:22466–70. doi: 10.1074/jbc.273.35.22466
98. Hemming R, Martin DC, Slominski E, Nagy JI, Halayko AJ, Pind S, et al. Mouse HYAL3 it encodes a 45-56-kDa glycoprotein overexpression increases whose hyaluronidase 1 activity in cultured cells. Glycobiology. (2008) 18:280–9. doi: 10.1093/glycob/cwn006
99. Berenbaum F. Osteoarthritis as an inflammatory disease. (osteoarthritis is not osteoarthrosis!). Osteoarthr Cartil. (2013) 21:16–21. doi: 10.1016/j.joca.2012.11.012
100. Horton WEJr, Bennion P, Yang L. Cellular, molecular, and matrix changes in cartilage during aging and osteoarthritis. J Musculoskelet Interact. (2006) 6:379–81. Available online at: http://www.ismni.org/jmni/pdf/26/31horton.pdf
101. Samuels J, Krasnokutsky S, Abramson SB. Osteoarthritis: a tale of three tissues. Bull NYU Joint Dis. (2008) 66:244–50.
102. Man G, Mologhianu G. Osteoarthritis pathogenesis- A complex process that involves the entire joint. J Med Life. (2014) 7:37–41. Available online at: http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3956093
103. Cope PJ, Ourradi K, Li Y, Sharif M. Models of osteoarthritis: the good, the bad and the promising. Osteoarthr Cartil. (2019) 27:230–9. doi: 10.1016/j.joca.2018.09.016
104. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years. (DALYs). for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. (2012) 380:2197–223. doi: 10.1016/S0140-6736(12)61690-0
105. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, Daigle ME, et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res. (2013) 65:703–11. doi: 10.1002/acr.21898
106. Hunter DJ. Viscosupplementation for osteoarthritis of the knee. New Engl J Med. (2015) 372:1040–7. doi: 10.1056/NEJMct1215534
107. Bowman S, Awad ME, Hamrick MW, Hunter M, Fulzele S. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clin Trans Med. (2018) 7:6. doi: 10.1186/s40169-017-0180-3
108. Cucchiarini M, de Girolamo L, Filardo G, Oliveira JM, Orth P, Pape D, et al. Basic science of osteoarthritis. J Exp Orthop. (2016) 3:22. doi: 10.1186/s40634-016-0060-6
109. Song J, Baek IJ, Chun CH, Jin EJ. Dysregulation of the NUDT7-PGAM1 axis is responsible for chondrocyte death during osteoarthritis pathogenesis. Nat Commun. (2018) 9:3427. doi: 10.1038/s41467-018-05787-0
110. Mobasheri A, Matta C, Zakany R, Mucumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas. (2015) 80:237–44. doi: 10.1016/j.maturitas.2014.12.003
111. Studer R, Jaffurs D, Stefanovic-Racic M, Robbins PD, Evans CH. Nitric oxide in osteoarthritis. Osteoarthr Cartil. (1999) 7:377–9. doi: 10.1053/joca.1998.0216
112. Yudoh K, Nguyen T, Nakamura H, Hongo-Masuko K, Kato T, Nishioka K, et al. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: Oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. Arthr Res Ther. (2005) 7:R380–91. doi: 10.1186/ar1499
113. Murphy CL, Thoms BL, Vaghjiani RJ, Lafont JE. HIF-mediated articular chondrocyte function: Prospects for cartilage repair. Arthr res Ther. (2009) 11:213. doi: 10.1186/ar2574
114. Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: Is osteoarthritis a chronic wound? Curr Opin Rheumatol. (2008) 20:565–72. doi: 10.1097/BOR.0b013e32830aba34
115. Svala E, Jin C, Rüetschi U, Lindahl A, Karlsson NG, Skiöldebrand E. Characterization of lubricin in synovial fluid from horses with osteoarthritis. Equine Vet J. (2017) 49:116–23. doi: 10.1111/evj.12521
116. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. (2011) 7:33–42. doi: 10.1038/nrrheum.2010.196
117. Song J, Kang YH, Yoon S, Chun C-H, Jin E-J. HIF-1alpha: CRAT: miR-144-3p axis dysregulation promotes osteoarthritis chondrocytes apoptosis and VLCFA accumulation. Oncotarget. (2017) 8:69351–61. doi: 10.18632/oncotarget.20615
118. Bolduc JA, Collins JA, Loeser RF. Reactive oxygen species, aging and articular cartilage homeostasis. Free Radic Biol Med. (2019) 132:73–82. doi: 10.1016/j.freeradbiomed.2018.08.038
119. Lepetos P, Papavassiliou KA, Papavassiliou AG. Redox and NF-κB signaling in osteoarthritis. Free Radic Biol Med. (2019) 132:90–100. doi: 10.1016/j.freeradbiomed.2018.09.025
120. Gu R, Liu N, Luo S, Huang W, Zha Z, Yang J. MicroRNA-9 regulates the development of knee osteoarthritis through the NF-kappaB1 pathway in chondrocytes. Medicine. (2016) 95:e4315. doi: 10.1097/MD.0000000000004315
121. Rasheed Z, Al-Shobaili HA, Rasheed N, Mahmood A, Khan MI. MicroRNA-26a-5p regulates the expression of inducible nitric oxide synthase via activation of NF-kappaB pathway in human osteoarthritis chondrocytes. Arch Biochem Biophys. (2016) 594:61–7. doi: 10.1016/j.abb.2016.02.003
122. Wang X, Guo Y, Wang C, Yu H, Yu X, Yu H. MicroRNA-142-3p inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1. Inflammation. (2016) 39:1718–28. doi: 10.1007/s10753-016-0406-3
123. Yin X, Wang JQ, Yan SY. Reduced miR26a and miR26b expression contributes to the pathogenesis of osteoarthritis via the production of p65 translocation. Mol Med Rep. (2017) 15:551–8. doi: 10.3892/mmr.2016.6035
124. Hu J, Wang Z, Pan Y, Ma J, Miao X, Qi X, et al. MiR-26a and miR-26b mediate osteoarthritis progression by targeting FUT4 via NF-kappaB signaling pathway. Int J Biochem Cell Biol. (2018) 94:79–88. doi: 10.1016/j.biocel.2017.12.003
125. Zhang D, Cao X, Li J, Zhao G. MiR-210 inhibits NF-kappaB signaling pathway by targeting DR6 in osteoarthritis. Sci Rep. (2015) 5:12775. doi: 10.1038/srep12775
126. Wei ZJ, Liu J, Qin J. miR-138 suppressed the progression of osteoarthritis mainly through targeting p65. Eur Rev Med Pharmacol Sci. (2017) 21:2177–84. Available online at: http://www.europeanreview.org
127. Blanco JF, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol. (1995) 146:75–85.
128. Adams CS, Horton WE Jr. Chondrocyte apoptosis increases with age in the articular cartilage of adult animals. Anat Rec. (1998) 250:418–25. doi: 10.1002/(SICI)1097-0185(199804)250:4<418::AID-AR4>3.3.CO;2-B
129. Kim HA, Suh DI, Song YW. Relationship between chondrocyte apoptosis and matrix depletion in human articular cartilage. J Rheumatol. (2001) 28:2038–45. Available online at: http://www.researchgate.net
130. Kim HA, Blanco FJ. Cell death and apoptosis in osteoarthritic cartilage. Curr Drug Targets. (2007) 8:333–45. doi: 10.2174/138945007779940025
131. Hwang HS, Kim HA. Chondrocyte apoptosis in the pathogenesis of osteoarthritis. Int J Mol Sci. (2015) 16:26035–54. doi: 10.3390/ijms161125943
132. Charlier E, Relic B, Deroyer C, Malaise O, Neuville S, Collee J, et al. Insights on molecular mechanisms of chondrocytes death in osteoarthritis. Int J Mol Sci. (2016) 17:2146. doi: 10.3390/ijms17122146
133. Miwa M, Saura R, Hirata S, Hayashi Y, Mizuno K, Itoh H. Induction of apoptosis in bovine articular chondrocyte by prostaglandin E2 through cAMP-dependent pathway. Osteoarthr Cartil. (2000) 8:17–24. doi: 10.1053/joca.1999.0266
134. Grishko V, Xu M, Ho R, Xu M, Ho R, Mates A, et al. Effects of hyaluronic acid on mitochondrial function and mitochondria-driven apoptosis following oxidative stress in human chondrocytes. J Biol Chem. (2009) 284:9132–9. doi: 10.1074/jbc.M804178200
135. Hashimoto S, Setareh M, Ochs RL, Lotz M. Fas/Fas ligand expression and induction of apoptosis in chondrocytes. Arthr Rheumatol. (1997) 40:1749–55. doi: 10.1002/art.1780401004
136. Blanco FJ, Lopez-Armada MJ, Maneiro E. Mitochondrial dysfunction in osteoarthritis. Mitochondrion. (2004) 4:715–28. doi: 10.1016/j.mito.2004.07.022
137. Cillero-Pastor B, Martin MA, Arenas J, Arenas J, Lopez-Armada MJ, Blanco FJ. Effect of nitric oxide on mitochondrial activity of human synovial cells. BMC Musculoskelet Disord. (2011) 12:42. doi: 10.1186/1471-2474-12-42
138. Del Carlo M Jr, Loeser RF. Nitric oxide-mediated chondrocyte cell death requires the generation of additional reactive oxygen species. Arthr Rheumatol. (2002) 46:394–403. doi: 10.1002/art.10056
139. Lopez-Armada MJ, Caramés B, Martin MA, Cillero-Pastor B, Lires-Dean M, Fuentes-Boquete I, et al. Mitochondrial activity is modulated by TNFalpha and IL-1β in normal human chondrocyte cells. Osteoarthr Cartil. (2006) 14:1011–22. doi: 10.1016/j.joca.2006.03.008
140. Jamil Z, Sharif M. Chondrocyte apoptosis: a cause or consequence of osteoarthritis? Int J Rheum Dis. (2011) 14:159–66. doi: 10.1111/j.1756-185X.2011.01618.x
141. Lorenz H, Richter W. Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem. (2006) 40:135–63. doi: 10.1016/j.proghi.2006.02.003
142. Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of Hyalgan G-F 20 and a lower-molecular weight hyaluronan. Clin Ther. (1999) 21:1549–62. doi: 10.1016/S0149-2918(00)80010-7
143. Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study. Biorheology. (2011) 48:263–75. doi: 10.3233/BIR-2011-0596
144. Ludwig TE, McAllister JR, Lun V, Wiley P, Schmidt TA. Diminished cartilage-lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation. Arthr Rheum. (2012) 64:3963–71. doi: 10.1002/art.34674
145. Choi SC, Yoo MA, Lee SY, Lee HJ, Son DH, Jung J, et al. Modulation of biomechanical properties of hyaluronic acid hydrogels by crosslinking agents. J Biomed Mater Res A. (2015) 103:3072–80. doi: 10.1002/jbm.a.35437
146. Marshall KW, Manolopoulos V, Mancer K, Staples J, Damyanovich A. Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis. J Orthop Res. (2000) 18:416–25. doi: 10.1002/jor.1100180313
147. Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthr Rheum. (2004) 50:314–26. doi: 10.1002/art.11421
148. Asari A, Kanemitsu T, Kurihara H. Oral administration of high molecular weight hyaluronan. (900 kDa). controls immune system via Toll-like receptor 4 in the intestinal epithelium. J Biol Chem. (2010) 285:24751–8. doi: 10.1074/jbc.M110.104950
149. Jensen GS, Attridge VL, Lenninger MR, Benson KF. Oral intake of a liquid-high-molecular-weight hyaluronan associated with relief of chronic pain and reduced use of pain medication: results of a randomized, placebo-controlled double-blind pilot study. J Med Food. (2015) 18:95–101. doi: 10.1089/jmf.2013.0174
150. Marshall KW. Intra-articular hyaluronan therapy. Curr Opin Rheumatol. (2000) 12:468–74. doi: 10.1097/00002281-200009000-00022
151. Iannitti T, Lodi D, Palmieri B. Intra-articular injections for the treatment of osteoarthritis. Drug RD. (2011) 11:13–17. doi: 10.1007/BF03259791
152. Maudens P, Jordan O, Allémann E. Recent advances in intra-articular drug delivery systems for oateoarthritis therapy. Drug Discov Today. (2018) 23:1761–75. doi: 10.1016/j.drudis.2018.05.023
153. Armstrong S, Read R, Ghosh P. The effect of intra-articular hyaluronan on cartilage and subchondral bone changes in an ovine model of early osteoarthritis. J Rheumatol. (1994) 21:680–7.
154. Kuroki K, Cook JL, Kreeger JM. Mechanisms of action and potential uses of hyaluronan in dogs with osteoarthritis. J Am Vet Med Assoc. (2002) 221:944–50. doi: 10.2460/javma.2002.221.944
155. Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially omega-3 fatty acids. Int J Rheumatol. (2011) 2011:1–17. doi: 10.1155/2011/969012
156. Carapeba GOL, Cavaleti P, Nicácio GM, Brinholi RB, Giuffrida R, Cassu RN. Intra-articular hyaluronic acid compared to traditional conservative treatment in dogs with osteoarthritis associated with hip dysplasia. Evid-Based Compl Altern Med. (2016) 2016:20726921. doi: 10.1155/2016/2076921
157. Fraser JRE, Kimpton WG, Pierscionek BK, Cahill RN. The kinetics of hyaluronan in normal and acutely inflammed synovial joints: Exploratory observations with experimental arthritis in sheep. Semin Arthr Rheum. (1993) 22:9–17. doi: 10.1016/S0049-0172(10)80015-0
158. Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. (2009) 37:1636–44. doi: 10.1177/0363546508326984
159. Maheu E, Zaim M, Appelboom T, Jeka S, Maasalu K, Berenbaum F. Comparative efficacy and safety of two different molecular weight. (MW). hyaluronans F60027 and Hyalan G-F20 in symptomatic osteoarthritis of the knee. (KAO). Results of a non-inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol. (2011) 29:527–35. Available online at: http://www.researchgate.net
160. Weiss C, Band P. Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Clin Podiatr Med Surg. (1995) 12:497–517.
161. McIlwraith CW. Use of sodium hyaluronate. (Hyaluronan) in equine joint disease. Equine Vet Educ. (1997) 9:296–304. doi: 10.1111/j.2042-3292.1997.tb01747.x
162. Hilbert BJ, Rowley G, Antonas KN. Hyaluronic acid concentration in synovial fluid from normal and arthritic joints of horses. Austr Vet J. (1984) 61:22–4. doi: 10.1111/j.1751-0813.1984.tb07125.x
163. Balazs EA. The physical properties of synovial fluid and the special role of hyaluronan acid. In: Helfet A, editor. Disorders of the Knee. Philadelphia, PA: Lippincott JB, (1982) 61–74.
164. Tulamo RM, Heiskanen T, Salonen M. Concentration and molecular weight distribution of hyaluronate in synovial fluid from clinically normal horses and horses with diseased joints. Am J Vet Res. (1994) 55:710–5.
165. Philip MW. Clinical trial comparison of intra-articular sodium hyaluronan products in horses. J Equine Vet Sci. (1989) 9:39–40. doi: 10.1016/S0737-0806(89)80120-0
166. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Safety. (2000) 23:115–30. doi: 10.2165/00002018-200023020-00003
167. Hsieh YS, Yang SF, Lue KH, Chu SH, Lu KH. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. J Orthop Res. (2008) 26:475–84. doi: 10.1002/jor.20524
168. Tikiz C, Unlü Z, Sener A, Efe M, Tuzun C. Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis. Clin Rheumatol. (2005) 24:244–50. doi: 10.1007/s10067-004-1013-5
169. Kotevoglu N, Iyibozkurt PC, Hiz O, Toktas H, Kuran B. A prospective randomized controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int. (2006) 26:325–30. doi: 10.1007/s00296-005-0611-0
170. Huang T-L, Hsu H-C, Yang K-C, Yao CH, Lin FH. Effect of different molecular weight hyaluronans on osteoarthritis-related protein production in fibroblast-like synoviocytes from patients with tibia plateau fracture. J Trauma. (2010) 68:146–52. doi: 10.1097/TA.0b013e3181a92cf8
171. Presti D, Scott JE. Hyaluronan mediated protective effect against cell damage caused by enzymatically produced hydroxyl. (OH·) radicals is dependent on hyaluronan molecular mass. Cell Biochem Funct. (1994) 12:281–8. doi: 10.1002/cbf.290120409
172. Fukuda K, Dan H, Takayama M, Kumano F, Saitoh M, Tanaka S. Hyaluronic acid stimulates proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. J Pharmacol Exp Ther. (1996) 277:1672–5.
173. Fukuda K, Takayama M, Ueno M, Oh M, Asada S, Kumano F, et al. Hyaluronic acid inhibits interleukin-1-induced superoxide anion in bovine chondrocytes. Inflamm Res. (1997) 46:114–7. doi: 10.1007/s000110050132
174. Fukuda K, Oh M, Asada S, Hara F, Matsukawa M, Otani K, et al. Sodium hyaluronate inhibits interleukin-1-evoked reactive oxygen species of bovine articular chondrocytes. Osteoarthr Cartil. (2001) 9:390–2. doi: 10.1053/joca.2000.0400
175. Maneiro E, de Andres MC, Ferández-Sueiro JL, Galdo F, Blanco FJ. The biological action of hyaluronan on human osteoarthritic articular chondrocytes: the importance of molecular weight. Clin Exp Rheumatol. (2004) 22:307–12. Available online at: http://www.researchgate.net/publication/8562181
176. Gocmen G, Gonul O, Oktay NS, Yarat A, Goker K. The antioxidant and anti-inflammatory efficiency of hyaluronic acid after third molar extraction. J Cranio-Maxillofac Surg. (2015) 43:7. doi: 10.1016/j.jcms.2015.04.022
177. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthr Res Ther. (2003) 5:R122–31. doi: 10.1186/ar748
178. Masuko K, Murata M, Yudoh K, Kato T, Nakamura H. Anti-inflammatory effects of hyaluronan in arthritis therapy: not just for viscosity. Int J Med. (2009) 2:77–81. doi: 10.2147/IJGM.S5495
179. Punji I, Schiavon F, Cavasin F, Ramonda R, Gambari PF, Todesco S. The influence of intra-articular hyaluronic acid on PGE2 and cAMP of synovial fluid. Clin Exp Rheumatol. (1989) 7:247–50.
180. Sasaki A, Sasaki K, Konttinen YT, Santavirta S, Takahara M, Takei H, et al. Hayluronan inhibits the interleukin-1beta-induced expression of matrix metalloproteinase. (MMP)-1 and MMP-3 in human synovial cells. Tohoku J Exp Med. (2004) 204:99–107. doi: 10.1620/tjem.204.99
181. Tanaka M, Masuko-Hongo K, Kato T, Nishioka K, Nakamura H. Suppressive effects of hyaluronan on MMP-1 and RANTES production from chondrocytes. Rheumatol Int. (2006) 26:185–90. doi: 10.1007/s00296-004-0547-9
182. Wang C-T, Lin Y-T, Chiang B-L, Lin Y-H, Hou S-M. High molecular-weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthr Cartil. (2006) 14:1237–47. doi: 10.1016/j.joca.2006.05.009
183. Yasui T, Adatsuka M, Tobetto K, Hayaishi M, Ando T. The effect of hyaluronan on interleukin-1-α-induced prostaglandin-E2 production in human osteoarthritic synovial cells. Agents Actions. (1992) 37:155–6. doi: 10.1007/BF01987905
184. Nonaka T, Kikuchi H, Ikeda T, Okamoto Y, Hamanishi C, Tanaka S. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol Suppl. (2000) 27:997–1004.
185. Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheumatol. (2005) 17:624–8. doi: 10.1097/01.bor.0000172800.49120.97
186. Gingerich DA, Auer JA, Fackelman GE. Effect of exogenous hyaluronic acid on joint function in experimentally induced equine osteoarthritis: Dosage titration studies. Res Vet Sci. (1981) 30:192–7. doi: 10.1016/S0034-5288(18)32580-3
187. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory response to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res. (1997) 116:3–9. doi: 10.1007/PL00005742
188. Pawlak M, Gomis A, Just S, Heppelmann B, Belmonte C, Schmidt RF. Mechanoprotective actions of elastoviscous hyalans on articular pain receptors. In Kennedy JF, Phillips GO, Williams PA, Hascall VC, editors. Hyaluronan 2000. Cambridge: Woodhead Publ, (2000).
189. De la Pina E, Sala S, Rovira JC, Schmidt RF, Belmonte C. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. Pain. (2002) 99:501–8. doi: 10.1016/S0304-3959(02)00260-9
190. Nelson FR, Zvirbulis RA, Zonca B, Li KW, Turner SM, Pasierb M, et al. The effects of an oral preparation containing hyaluronic acid. (Oralvisc®) on obese knee osteoarthritis patients determined by pain, function, bradykinin, leptin, inflammatory cytokines, and heavy water analysis. Rheumatol Int. (2015) 35:43–52. doi: 10.1007/s00296-014-3047-6
191. Smith MM, Russell AK, Schiavinato A, Little CV. A hexadecylamide derivative of hyaluronan. (HYMOVIS®). has superior beneficial effects on human osteoarthritic chondrocytes and synoviocytes than unmodified hyaluronan. J Inflamm. (2013) 10:26. doi: 10.1186/1476-9255-10-26
192. Julovi SM, Ito H, Nishitani K, Jackson CJ, Nakamura T. Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and p38. J Orthop Res. (2011) 29:258–64. doi: 10.1002/jor.21216
193. Yatabe T, Mochizuki S, Takizawa M, Chijiiwa M, Okada A, Kimura T, et al. Hyaluronan inhibits expression of ADAMTS4. (aggrecanase-1). in human osteoarthritic chondrocytes. Ann Rheum Dis. (2009) 68:1051–8. doi: 10.1136/ard.2007.086884
194. Yoshimi T, Kiruchi T, Obara T, Yamaguchi T, Sakakibara Y, Itoh H, et al. Effects of high-molecular-weight sodium hyaluronate on experimental osteoarthrosis induced by the resection of rabbit anterior cruciate ligament. Clin Orthop Rel Res. (1994) 298:296–304. doi: 10.1097/00003086-199401000-00039
195. Kikuchi T, Yamada H, Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthr Cartil. (1996) 4:99–110. doi: 10.1016/S1063-4584(05)80319-X
196. Shimizu C, Kubo T, Hirasawa Y, Coutts RD, Amiel D. Histomorphometric and biochemical effect of various hyaluronans on early osteoarthritis. J Rheumatol. (1998) 25:1813–9.
197. Frean S, Abraham L, Lees P. in vitro stimulation of equine articular cartilage proteoglycan synthesis by hyaluronan and carprofen. Res Vet Sci. (1999) 67:183–90. doi: 10.1053/rvsc.1999.0328
198. Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol. (2000) 27:1713–20.
199. Zhou J-L, Liu S-Q, Qiu B, Hu Q-J, Ming J-H, Peng H. The protective effect of sodium hyaluronate on the cartilage of rabbit osteoarthritis by inhibiting peroxisome proliferator-activated receptor-gamma messenger RNA expression. Yonsei Med J. (2009) 50:832–7. doi: 10.3349/ymj.2009.50.6.832
200. Siczkowski M, Andrew T, Amos S, Gordon MY. Hyaluronic acid regulates the function and distribution of sulfated glycosaminoglycans in bone marrow stromal cultures. Exp Hematol. (1993) 21:126–30.
201. Goto H, Onodera T, Hirano H, Shimamura T. Hyaluronic acid suppresses the reduction of alpha2(VI). collagen gene expression caused by interleukin-1beta in cultured rabbit articular chondrocytes. Tohoku J Exp Med. (1999) 187:1–13. doi: 10.1620/tjem.187.1
202. Lisignoli G, Grassi F, Zini N, Toneguzzi S, Piacentini A, Guidolin D, et al. Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: evidence for CD44 and CD54. (intercellular adhesion molecule 1). involvement. Arthr Rheum. (2001) 44:1800–7. doi: 10.1002/1529-0131(200108)44:8<1800::AID-ART317>3.0.CO;2-1
203. Cao JJ, Singleton PA, Majumdar S, Boudignon B, Burghardt A, Kurimoto P, et al. Hayluronan increases RANKL expression in bone marrow stromal cells through CD44. J Bone Miner Res. (2005) 20:30–40. doi: 10.1359/jbmr.2005.20.1.30
204. Borzachhiello A, Mayol L, Ambrosio I, Nicolais L, Schiavinato A. “Evaluation of a novel hyaluronic acid derivative on synovial fluid viscoelastic properties,” in Biomaterials: European Conference on 2002:19.
205. Brun P, Zavan B, Vindigni V, Schiavinato A, Pozzuoli A, Iacobellis C, et al. in vitro response of osteoarthritic chondrocytes and fibroblast-like synoviocytes to a 500-730 kDa hyaluronan amide derivative. J Biomed Mater Res B Appl Biomater. (2012) 100:2073–81. doi: 10.1002/jbm.b.32771
206. Cake MA, Read R, Edwards S, Smith MM, Burkhardt D, Little C, et al. Changes in gait after bilateral meniscectomy in sheep: Effect of two hyaluronan preparations. J Orthop Sci. (2008) 13:514–23. doi: 10.1007/s00776-008-1279-6
207. Smith MM, Cake MA, Ghosh P, Schiavinato A, Read RA, Little CB. Significant synovial pathology in a meniscectomy model of osteoarthritis: Modification by intra-articular hyaluronan therapy. Rheumatology. (2008) 47:1172–8. doi: 10.1093/rheumatology/ken219
208. Sanchez C, Bay-Jensen A-C, Pap T, Dvir-Ginzberg M, Quasnichka H, Barrett-Jolley R, et al. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. Osteoarthr Cartil. (2017) 25:1199–209. doi: 10.1016/j.joca.2017.02.797
209. Archer CW, Francis-West P. The chondrocyte. Int J Biochem Cell Biol. (2003) 35:401–4. doi: 10.1016/S1357-2725(02)00301-1
210. Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthr Cartil. (2009) 17:971–9. doi: 10.1016/j.joca.2009.03.002
211. Martin JA, Buckwalter JA. Aging, articular cartilage chondrocyte senescence and osteoarthritis. Biogerontology. (2002) 3:257–64. doi: 10.1023/A:1020185404126
212. Palmoski M, Brandt K. Hyaluronate-binding by proteoglycans: comparison of mildly and severely osteoarthritic regions of human femoral cartilage. Clin Chim Acta. (1976) 70:87–95. doi: 10.1016/0009-8981(76)90008-5
213. Pelletier JP, Martell-Pelletier J. Evidence for the involvement of interleukin-1 in human osteoarthritic cartilage degradation. Protective effects of NSAIDS. J Rheumatol. (1989) 16:19–27. doi: 10.1016/0049-0172(89)90080-2
214. Okada Y, Shinmei M, Tanaka O, Naka K, Kimura A, Nakanishi I, et al. Localization of matrix metalloproteinase 3. (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest. (1992) 66:680–90.
215. Knott I, Dieu M, Burton M. Induction of cyclooxygenase by interleukin 1: comparative study between human synovial cells and chondrocytes. J Rheumatol. (1994) 21:462–6.
216. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun. (1994) 200:142–8. doi: 10.1006/bbrc.1994.1426
217. Chang EJ, Kim HJ, Ha J, Kim HJ, Ryu J, Park KH, et al. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci. (2007) 120:166–76. doi: 10.1242/jcs.03310
218. Goto S, Miyazaki K, Onaya J. Experimental knee pain model in rats and analgesic effect of sodium hyaluronate. Folia Pharmacol JPN. (1988) 92:17–27. doi: 10.1254/fpj.92.17
219. Amiel D, Toyoguchi T, Kobayashi K, Bowden K, Amiel ME, et al. Long-term effect of sodium hyaluronate. (Hyalgan®) on osteoarthritis progression in a rabbit model. Osteoarthr Cartil. (2003) 11:636–43. doi: 10.1016/S1063-4584(03)00119-5
220. Mainil-Varlet P, Schiavinato A, Ganster MM. Efficacy evaluation of a new hyaluronan derivative HYADD® 4-G to maintain cartilage integrity in a rabbit model of osteoarthritis. Cartilage. (2013) 4:28–41. doi: 10.1177/1947603512455193
221. Roach HI, Aigner T, Kouri JB. Chondroptosis: a variant of apoptotic cell death in chondrocytes? Apoptosis. (2004) 9:265–77. doi: 10.1023/B:APPT.0000025803.17498.26
222. Shan ZZ, Masuko-Hongo K, Dai SM, Nakamura H, Kato T, Nishioka K. A potential role of 15-deoxy. (12:14). prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J Biol Chem. (2004) 279:37939–50. doi: 10.1074/jbc.M402424200
223. Ghosh P, Read R, Armstrong S, Wilson D, Marshall R, McNair P. The effects of intraarticular administration of hyaluronan in a model of early oateoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Semin Arthr Rheum. (1993) 22(Suppl 1):18–30. doi: 10.1016/S0049-0172(10)80016-2
224. Ghosh P, Read R, Numata Y, Smith S, Armstrong S, Wilson D. The effects of intraarticular administration of hyaluronan in a model of early oateoarthritis in sheep. II. Cartilage composition and proteoglycan metabolism. Semin Arthr Rheum. (1993) 22(Suppl. 1):31–42. doi: 10.1016/S0049-0172(10)80017-4
225. Carney SL, Billingham ME, Muir H, Sandy JD. Structure of newly synthesized. (35S)-proteoglycans and. (35S)-proteoglycan turnover products of cartilage explant cultures from dogs with experimental osteoarthritis. J Orthop Res. (1985) 3:140–7. doi: 10.1002/jor.1100030203
226. Myers SL, Brandt KD. Studies of synovial hyaluronic acid synthesis in canine osteoarthritis. J Rheumatol. (1987) 14:1150–5.
227. Adams ME, Pelletier JP. The canine anterior cruciate ligament transection model of osteoarthritis. In: Greenwald RA, Diamond HS, editors. Handbook of Models of Arthritis Research. Boca Raton FL: CRC Press, (1988), 265–297.
228. Meyers SL, Brandt KD, O'Connor BL, Visco DM, Albrecht ME. Synovitis and osteoarthritic changes in canine articular cartilage after anterior cruciate ligament transection: Effect of surgical homeostasis. Arthr Rheum. (1990) 33:1406–15. doi: 10.1002/art.1780330913
229. Adams ME, Brandt KD. Hypertrophic repair of canine articular cartilage in osteoarthritis after anterior cruciate ligament transection. J Rheumatol. (1991) 18:428–35.
230. Kuyinu EL, Narayanan G, Nair LS, Laurencin CT. Animal models of osteoarthritis: Classification, update, and measurement of outcomes. J Orthop Surg Res. (2016) 11:19. doi: 10.1186/s13018-016-0346-5
231. Deckers C, Stephan P, Wever KE, Hooijmans CR, Hannink G. The protective effect of anterior cruciate ligament reconstruction on articular cartilage: a systematic review of animal studies. Osteoarthr Cartil. (2019) 27:219–29. doi: 10.1016/j.joca.2018.10.001
232. Meyers SL, Brandt KD. Studies of synovial hyaluronic acid synthesis in canine osteoarthritis. J Rheumatol. (1987) 14:1150–5.
233. Smith GN Jr, Myers SL, Brandt KD, Mickler EA. Effect of intraarticular hyaluronan injection in experimental canine osteoarthritis. Arthr Rheumatol. (1998) 41:976–85. doi: 10.1002/1529-0131(199806)41:6<976::AID-ART4>3.0.CO;2-R
234. McDevitt CA, Muir H. Biochemical changes in the cartilage of the knee in experimental and natural osteoarthritis in the dog. J Bone Joint Surg Br. (1976) 58:94–101. doi: 10.1302/0301-620X.58B1.131804
235. Abatangelo G, Botti P, Del Bue M, Gei G, Samson JC, Cortivo R, et al. Intra-articular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. I Biochemical results. Clin Orthop Relat Res. (1989) 241:278–85. doi: 10.1097/00003086-198904000-00037
236. Schiavinato A, Lini E, Guidolin D, Pezzoli G, Botti P, Martelli M, et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. II Morphological findings. Clin Orthop Relat Res. (1989) 241:286–99. doi: 10.1097/00003086-198904000-00038
237. Pak DR, Ko R, Kwon SH, Min B, Yun SH, Kim MH, et al. FlexPro, M. D, a mixture of krill oil, astaxanthin, hyaluronic acid, suppresses lipopolysaccharide-induced inflammatory cytokine production though inhibition of NF-κB. J Med Food. (2016) 19:1196–203. doi: 10.1089/jmf.2016.3787
238. Åsheim Å, Lindblad G. Intra-articular treatment of arthritis in racehorses with sodium hyaluronate. Acta Vet Scand. (1976) 17:379–94.
239. Rose RJ. The intra-articular use of sodium hyaluronate for the treatment of osteoarthrosis in the horse. NZ Vet J. (1979) 27:5–8. doi: 10.1080/00480169.1979.34585
240. Selway SJ. Notes on the use of sodium hyaluronate in Thoroughbreds. J EVS. (1985) 5:236–7. doi: 10.1016/S0737-0806(85)80106-4
241. Galley RH. The use of hyaluronic acid in the racehorse. Proc Am Assoc Equine Pract. (1986) 32:657–61.
242. Auer JA, Fackelman GE, Gingerich DA, Fetter AW. Effect of hyaluronic acid in naturally occurring and experimentally induced osteoarthritis. Am J Vet Res. (1980) 41:568–74.
243. Gingerich DA, Auer JA, Fackelman GE. Force plate studies on the effect of exogenous hyaluronic acid on joint function in equine arthritis. J Vet Pharmacol Ther. (1979) 2:291–8. doi: 10.1111/j.1365-2885.1979.tb00403.x
244. Niemelä TM, Tulamo R-M, Hielm-Björkman AK. A randomized, double-blinded, placebo-controlled clinical study on intra-articular hyaluronan treatment in equine lameness originating from the metacarpophalangeal joint. BMC Vet Res. (2016) 12:60. doi: 10.1186/s12917-016-0687-7
245. Irwin DHG. Sodium hyaluronate in equine traumatic arthritis. J South Afr Vet Assoc. (1980) 50:231–3.
246. Ruth DT, Swites BJ. Comparison of the effectiveness of intra-articular hyaluronic acid and conventional therapy for the treatment of naturally occurring arthritic conditions in equine. Equine Pract. (1985) 7:25–9.
247. Gaustad G, Larsen S. Comparison of polysulfated glycosaminoglycan and sodium hyaluronate with placebo in treatment of traumatic arthritis in horses. Equine Vet J. (1995) 27:356–62. doi: 10.1111/j.2042-3306.1995.tb04070.x
248. Richardson DW, Loinaz R. An evidence-based approach to selected joint therapies in horses. Vet Clin North Am: Equine Pract. (2007) 23:443–60. doi: 10.1016/j.cveq.2007.04.007
249. Frisbie DD, McIlwraith CW, Kawcak CE, Werpy NM. Efficacy of intravenous administration of hyaluronan, sodium chondroitin sulfate, and N-acetyl-D-glucosamine for prevention or treatment of osteoarthritis in horses. Am J Vet Res. (2016) 77:1064–70. doi: 10.2460/ajvr.77.10.1064
250. Berenbaum F, Grifka J, Cazzaniga S, D'Amato M, Giacovelli G, Chevalier X, et al. A randomized, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis. (2012) 71:1454–60. doi: 10.1136/annrheumdis-2011-200972
251. Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee. Clinical efficacy and economic implications. Drugs Aging. (2007) 24:629–42. doi: 10.2165/00002512-200724080-00002
252. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. (2004) 86-A:538–45. doi: 10.2106/00004623-200403000-00012
253. Pritchard CH, Sripada P, Bankes PF, Smith DG, Schneider D. A retrospective comparison of the efficacy and tolerability of sodium hyaluronate and hylan G-F 20 in the treatment of osteoarthritis of the knee. J Musculoskel Res. (1999) 6:197–205. doi: 10.1142/S021895770200085X
254. Lo GH, LaValley M, McAlindon T, Felson D. Intra-articular hyaluronic acid in treatment of knee oateoarthritis: a meta-analysis. JAMA. (2004) 290:3115–21. doi: 10.1001/jama.290.23.3115
255. Santilli V, Paoloni M, Mangone M, Mangone M, Alviti F, Bernetti A. Hyaluronic acid in the management of osteoarthritis: injection therapies innovations. Clin Cases Miner Bone Metab. (2016) 13:131–4. doi: 10.11138/ccmbm/2016.13.2.131
256. Goldberg V, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthr Cartil. (2005) 13:216–24. doi: 10.1016/j.joca.2004.11.010
257. Neustadt D, Caldwell J, Bell M, Wade J, Gimbel J. Clinical effects of intraarticular injection of high molecular weight hyaluronan. (Orthovisc) in osteoarthritis of the knee: A randomized, controlled, multicenter trial. J Rheumatol. (2005) 32:1928–36. Available online at: http://www.jrheum.org/content/32/10/1928
258. Venable RO, Stoker AM, Cook CR, Cockrell MK, Cook JL. Examination of synovial fluid hyaluronan quantity and quality in stifle joints of dogs with osteoarthritis. Am J Vet Res. (2008) 69:1569–73. doi: 10.2460/ajvr.69.12.1569
259. Aubry-Rozier B. Role of slow-acting anti-arthritic agents in osteoarthritis. (chondroitin sulfate, glucosamine, hyaluronic acid). Rev Med Suisse. (2012) 14:571–2.
260. Listrat V, Ayral X, Patarnello F, Bonvarlet J-P, Simonnet J, Armor B, et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan. (Hyaglan) in osteoarthritis of the knee. Osteoarthr Cartil. (1997) 5:153–60. doi: 10.1016/S1063-4584(97)80010-6
261. Jubb RW, Piva S, Beinat L, Dacre J, Gishen PA. A one-year, randomized placebo. (saline). controlled clinical trial of 500-730 kDa sodium hyaluronate. (Hyalgan). on the radiological change in osteoarthritis of the knee. Int J Clin Pract. (2003) 57:467–74. Available online at: http://discovery.ucl.ac.uk/id/eprint/10073924
262. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology. (2002) 41:1240–8. doi: 10.1093/rheumatology/41.11.1240
263. Karatosum V, Unver B, Gocen Z, Sen A. Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee: a prospective, randomized, double-blind study with long-term follow-up. Clin Exp Rheumatol. (2005) 23:213–8.
264. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthr Cartil. (2006) 14:154–62. doi: 10.1016/j.joca.2005.09.003
265. Juni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B, et al. Efficacy and safety of intraarticular Hylan or hyaluronic acids for osteoarthritis of the knee. A randomized controlled trial. Arthr Rheum. (2007) 56:3610–9. doi: 10.1002/art.23026
266. Reichenbach S, Blank S, Rutjes AW, Shang A, King EA, Dieppe PA. Hylan versus hyaluronic acid for osteoarthritis of the knee: A symptomatic review and meta-analysis. Arthr Rheum. (2007) 57:1410–8. doi: 10.1002/art.23103
267. Raman R, Dutta A, Sharma HK, Shaw CJ, Johnson GV. Efficacy of Hylan G-F20 and sodium hyaluronate in the treatment of osteoarthritis of the knee. A prospective randomized clinical trial. Knee. (2008) 15:318–24. doi: 10.1016/j.knee.2008.02.012
268. Tashiro T, Seino S, Sato T, Matsuoka R, Masuda Y, Fukui N. Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis: a double-blind, placebo-controlled study over a 12-month period. Scientif World J. (2012) 2012:167928. doi: 10.1100/2012/167928
269. Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. (2012) 157:180–91. doi: 10.7326/0003-4819-157-3-201208070-00473
270. Weigel PH, Fuller GM, LeBoeuf RD. A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J Theoret Biol. (1986) 11:219–34. doi: 10.1016/S0022-5193(86)80076-5
271. Tammi R, Tammi M, Häkkinen L, Larjava H. Histochemical localization of hyaluronate in human oral epithelium using a specific hyaluronate-binding probe. Arch Oral Biol. (1990) 35:219–24. doi: 10.1016/0003-9969(90)90058-I
272. Oksala O, Salo T, Tammi R, Hakkinen L, Jalkanen M, Inki P, et al. Expression of proteoglycans and hyaluronan during wound healing. J Histochem Cytochem. (1995) 43:125–35. doi: 10.1177/43.2.7529785
273. Olczyk P, Komosinska-Vassev K, Winsz-Szczotka K, Kuznik-Trocha K, Olczyk K. Hyaluronan: structure, metabolism, functions, and role in wound healing. Postepy Hig Med Dosw. (2008) 62:651–9. Available online at: http://www.researchgate.net/publication/23572451
274. Gao F, Liu Y, He Y, Yang C, Wang Y, Shi X, et al. Hyaluronan oligosaccharides promote excisional wound healing through enhanced angiogenesis. Matrix Biol. (2010) 29:107–16. doi: 10.1016/j.matbio.2009.11.002
275. Neuman MG, Nanau RM, Oruña-Sanchez L, Coto G. hyaluronic acid and wound healing. J Pharm Pharm Sci. (2015) 18:53–60. doi: 10.18433/J3K89D
276. Picker LJ, Nakache M, Butcher EC. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol. (1989) 109:927–37. doi: 10.1083/jcb.109.2.927
277. Wang C, Tammi M, Tammi R. Distribution of hyaluronan and its CD44 receptor in the epithelia of human skin appendages. Histochemistry. (1992) 98:105–12. doi: 10.1007/BF00717001
278. Kaya G, Stamenkovic I, Vassalli P, Jorcano JL, Rodriguez I. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. (1997) 15:996–1007. doi: 10.1101/gad.11.8.996
279. Weigel PH, Frost SJ, LeBoeuf RD, McGary CT. The specific interaction between fibrin(ogen). and hyaluronan: possible consequences in hemostasis, inflammation and wound healing. In: Eveted D, Whelan J, editors. The Biology of Hyaluronan. Ciba Foundation Symposium 143. Chichester: Wiley, (1989) p. 248–261.
280. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. (1985) 228:1324–6. doi: 10.1126/science.2408340
281. Aya KL, Stern R. Hyaluronan in wound healing: rediscovering a major player. Wound Repair Regener. (2014) 22:579–93. doi: 10.1111/wrr.12214
282. Sattar A, Rooney P, Kumar S, Pye D, West DC, Scott I, et al. Application of angiogenic oligosaccharides of hyaluronan increases blood vessel numbers in rat skin. J Invest Dermatol. (1994) 103:576–9. doi: 10.1111/1523-1747.ep12396880
283. Arnold F, Jia C, He C, Cherry GW, Carbow B, Meyer-Ingold W, et al. Hyaluronan, heterogeneity, and healing: the effects of ultrapure hyaluronan of defined molecular size on the repair of full-thickness of pig skin wounds. Wound Repair Reg. (1995) 3:299–310. doi: 10.1046/j.1524-475X.1995.30310.x
284. Lees VC, Fan TP, West DC. Angiogenesis is a delayed vascularization model is accelerated by angiogenic oligosaccharides of hyaluronan. Lab Invest. (1995) 73:259–66.
285. Bollyky PL, Bogdani M, Bollyky JB, Hull R, Wight TN. The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation. Curr Diab Rep. (2012) 12:471–80. doi: 10.1007/s11892-012-0297-0
286. Weigel PH, Frost SJ, McGary CT, LeBoeuf RD. The role of hyaluronic acid in inflammation and wound healing. Int J Tiss React. (1988) 10:355–65.
287. Tolg C, Telmer P, Turley E. Specific sizes of hyaluronan oligosaccharides stimulate fibroblast migration and excisional wound repair. Plos ONE. (2014) 9:e88479. doi: 10.1371/journal.pone.0088479
288. Goa KL, Benfield P. Hyaluronic acid: a review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs. (1994) 47:536–66. doi: 10.2165/00003495-199447030-00009
289. Vogel R, Crockett RS, Oden N, Laliberte TW, Molina L. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution. (vismed, rejena). Am J Ophthamol. (2010) 149:594–601. doi: 10.1016/j.ajo.2009.09.023
290. Rath MJ. A review of hyaluronan and its ophthalmic applications. Optometry. (2011) 82:38–43. doi: 10.1016/j.optm.2010.08.003
291. Williams DL, Mann BK. A crosslinked HA-based hydrogel ameliorates dry eye symptoms in dogs. Int J Biomaterials. (2013) 2013:460435. doi: 10.1155/2013/460437
292. Maulvi FA, Soni TG, Shah DO. Extended release of hyaluronic acid from hydrogel contact lenses for dry eye syndrome. J Biomater Sci Polym Ed. (2015) 26:1035–50. doi: 10.1080/09205063.2015.1072902
293. Salwowska NM, Bebenek K, Zadlo DA, Wcislo-Dziadecka DL. Physicochemical properties and application of hyaluronic acid: a systematic review. J Cosmet Dermatol. (2016) 15:520–6. doi: 10.1111/jocd.12237
294. Lee D, Lu Q, Sommerfeld SD, Chan A, Menon NG, Schmidt TA, et al. Targeted delivery of hyaluronic acid to the ocular surface by a polymer-peptide conjugate system for dry eye disease. Acta Biomater. (2017) 55:163–71. doi: 10.1016/j.actbio.2017.03.043
295. Hamano T, Horimoto K, Lee M, Kumemushi S. Sodium hyaluronate eyedrops enhance tear film stability. Jap J Ophthalmol. (1996) 40:62–5.
296. Inoue M, Katakami C. The effect of hyaluronic acid on corneal epithelial cell proliferation. Invest Ophthalmol Vis Sci. (1993) 34:2313–5.
297. Stiebel-Kalish H, Gaton DD, Weinberger D, Loya N, Schwartz-Ventik M, Solomon A. A comparison of the effect of hyaluronic acid versus gentamicin on corneal epithelial healing. Eye. (1998) 12:829–33. doi: 10.1038/eye.1998.213
298. Camillieri G, Bucolo C, Rossi S, Rossi S, Drago F. Hyaluronan-induced stimulation of corneal wound healing is a pure pharmacological effect. J Ocul Pharmacol Ther. (2004) 20:548–53. doi: 10.1089/1080768042727873
299. Yang G, Espandar L, Mamalis N, Prestwich GD. A crosslinked hyaluronan gel accelerates healing of corneal epithelial abrasion and alkali burn injuries in rabbits. Vet Ophthalmol. (2010) 13:144–50. doi: 10.1111/j.1463-5224.2010.00771.x
300. Ho WT, Chiang TH, Chang SW, Chen YH, Hu FR, Wang J. Enhanced corneal wound healing with hyaluronic acid and high-potassium artificial tears. Clin Exp Optom. (2013) 96:536e41. doi: 10.1111/cxo.12073
301. Laffleur F, Dachs S. Development of novel mucoadhesive hyaluronic acid derivate as lubricant for the treatment of dry eye syndrome. Ther Deliv. (2015) 6:1211–9. doi: 10.4155/tde.15.55
302. Koivusalo L, Karvinen J, Sorsa E, Jonkkari I, Valiaho J, Kallio P, et al. Hydrazone cross-linked hyaluronan-based hydrogels for therapeutic delivery of adipose stem cells to treat corneal defects. Mater Sci Eng C Mater Biol Appl. (2018) 85:68–78. doi: 10.1016/j.msec.2017.12.013
303. Holmberg AS, Philpson BT. Sodium hyaluronate in cataract surgery: I. Report on the use of Healon® in two different types of intracapsular cataract surgery. Ophthalmology. (1984) 91:45–52. doi: 10.1016/S0161-6420(84)34341-X
304. Wilson RP, Lloyd J. The place of sodium hyaluronate in glaucoma surgery. Ophthalmic Surg. (1986) 17:30–3.
305. Martens TF, Remaut K, Deschout H, Engbersen JFJ, Hennik WE, van Steenbergen MJ, et al. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J Controll Rel. (2015) 202:83–92. doi: 10.1016/j.jconrel.2015.01.030
306. Toole BP, Ghatak S, Misra S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol. (2008) 9:249–52. doi: 10.2174/138920108785161569
307. Montagner IM, Merlo A, Carpanese D, Zuccolotto G, Renier D, Campisi M, et al. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience. (2015) 2:373–81. doi: 10.18632/oncoscience.150
308. Stickeler E, Runnebaum IB, Mobus VJ, Kieback DG, Kreienberg R. Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines. Anticancer Res. (1997) 17:1871–6.
309. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem. (2002) 27:4589–92. doi: 10.1074/jbc.R100038200
310. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. (2011) 71:4085–95. doi: 10.1158/0008-5472.CAN-10-4610
311. Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ, et al. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget. (2015) 6:9313–26. doi: 10.18632/oncotarget.3220
312. Mattheolabakis G, Milane L, Singh A, Amiji MM. Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine. J Drug Target. (2015) 23:605–18. doi: 10.3109/1061186X.2015.1052072
313. Wu M, Cao M, He Y, Liu Y, Yang C, Du Y, et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J. (2015) 29:1290–8. doi: 10.1096/fj.14-259978
314. Hayward SL, Wilson CL, Kidambi S. Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells. Oncotarget. (2016) 7:34158–71. doi: 10.18632/oncotarget.8926
315. Wang T, Hou J, Su C, Zhao L, Shi Y. Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44. J Nanobiotechnol. (2017) 15:7. doi: 10.1186/s12951-016-0245-2
316. Parashar P, Rathor M, Dwivedi M, Saraf SA. Hyaluronic acid decorated naringenin nanoparticles: Appraisal of chemopreventive and curative potential for lung cancer. Pharmaceutics. (2018) 2018:10. doi: 10.3390/pharmaceutics10010033
317. Orian-Rousseau V. CD44 acts as a signaling platform controlling tumor progression and metastasis. Front Immunol. (2015) 6:154. doi: 10.3389/fimmu.2015.00154
318. Lesley J, Hascall VC, Tammi M, Hyman R. Hyaluronan binding by cell surface CD44. J Biol Chem. (2000) 275:26967–75. doi: 10.1074/jbc.M002527200
319. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem. (2002) 277:38013–20. doi: 10.1074/jbc.M202404200
320. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem. (2003) 278:25285–8. doi: 10.1074/jbc.C300173200
321. Misra S, Toole BP, Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem. (2006) 281:34936–41. doi: 10.1074/jbc.C600138200
322. Banzato A, Bobisse S, Rondina M, Renier D, Betella F, Esposito G, et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords in vivo therapeutic activity. Clin Cancer Res. (2008) 14:3598–606. doi: 10.1158/1078-0432.CCR-07-2019
323. Kim H, Park HT, Tae YM, Kong WH, Sung DK, Hwang BK, et al. Bioimaging and pulmonary applications of self-assembled Flt1 peptide-hyaluronic acid conjugate nanoparticles. Biomaterials. (2013) 34:8478–90. doi: 10.1016/j.biomaterials.2013.07.062
324. Mero A, Campisi M. Hyaluronic acid bioconjugates for the delivery of bioactive molecules. Polymers. (2014) 6:346–69. doi: 10.3390/polym6020346
325. Chen Y, Peng F, Song X, Wu J, Yao W, Gao X. Conjugation of paclitaxel to C-6 hexanediamine-modified hyaluronic acid for targeted drug delivery to enhance antitumor efficacy. Carbohydr Polym. (2018) 181:150–8. doi: 10.1016/j.carbpol.2017.09.017
326. Seto-Rogers S. Metastasis: multitasking hyaluronic acid. Nat Rev Cancer. (2012) 12:228. doi: 10.1038/nrc3254
327. Lokeshwar VB, Mirza S, Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res. (2014) 123:35–65. doi: 10.1016/B978-0-12-800092-2.00002-2
328. Negi LM, Jaggi M, Joshi V, Ronodip K, Talegaonkar S. Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer. Int J Biol Macromol. (2015) 73:222–35. doi: 10.1016/j.ijbiomac.2014.11.026
329. Han NK, Shin DH, Kim JS, Weon KY, Jang CY, Kim JS. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. Int J Nanomed. (2016) 11:1413–25. doi: 10.2147/IJN.S95850
330. Abate M, Salini V. Hyaluronic acid in the treatment of osteoarthritis: what is new. In: Chen Q, editor. Osteoarthritis-Diagnosis, Treatment and Surgery. Pescara: InTech (2012). p. 101–22.
331. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, Medicis RD, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. (1996) 23:1579–85.
332. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate. (Hyalgan®) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial. J Rheumatol. (1998) 25:2203–12.
333. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F-20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. (1998) 20:410–23. doi: 10.1016/S0149-2918(98)80052-0
334. Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group Clin Orthop. (2001) 385:130–43. doi: 10.1097/00003086-200104000-00021
Keywords: hyaluronic acid, hyaluronan, osteoarthritis, viscosupplementation, wound healing, ophthalmic diseases, adjuvant therapy, cancer therapy
Citation: Gupta RC, Lall R, Srivastava A and Sinha A (2019) Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front. Vet. Sci. 6:192. doi: 10.3389/fvets.2019.00192
Received: 04 March 2019; Accepted: 30 May 2019;
Published: 25 June 2019.
Edited by:
Nora Mestorino, National University of La Plata, ArgentinaReviewed by:
Piotr Bełdowski, University of Technology and Life Sciences in Bydgoszcz, PolandMaria-Rosa Martinez-Larrañaga, Complutense University of Madrid, Spain
Copyright © 2019 Gupta, Lall, Srivastava and Sinha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ramesh C. Gupta, rgupta@murraystate.edu